,AID,AID Version,AID Revision,Panel Member ID,SID,CID,Bioactivity Outcome,Target GI,Target GeneID,Activity Value [uM],Activity Name,Assay Name,Bioassay Type,PubMed ID,RNAi
0,1471,2,1,,50112790,3152,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
1,1490,2,1,,50112790,3152,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
2,1688,1,1,,50112790,3152,Inactive,90903231.0,3064.0,,Potency,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Aggregate Formation (GFP),Confirmatory,,
3,1766,1,1,,50112790,3152,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
4,1766,1,1,,50112790,3152,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
5,1768,1,1,,50112790,3152,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
6,1768,1,1,,50112790,3152,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
7,2528,1,2,,50112790,3152,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
8,2546,1,1,,50112790,3152,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
9,2551,1,1,,50112790,3152,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
10,2662,2,1,,50112790,3152,Inactive,56550039.0,4297.0,,Potency,qHTS Fluorescence Polarization Assay for Inhibitors of MLL CXXC domain - DNA interaction,Confirmatory,,
11,30243,9,1,,103172342,3152,Active,,,0.0053,IC50,In vitro inhibitory activity against acetylcholinesterase,Confirmatory,1738151.0,
12,30541,10,5,,103172342,3152,Active,14916521.0,,0.017,IC50,Compound was evaluated for the inhibition of acetylcholinesterase (AChE) in electric eel,Confirmatory,9871563.0,
13,30660,10,5,,103172342,3152,Active,543754.0,,0.012,IC50,Compound was evaluated for the inhibition of acetylcholinesterase (AChE) in Torpedo californica,Confirmatory,9871563.0,
14,30678,9,1,,103172342,3152,Active,,,0.006,IC50,Compound was evaluated for the inhibition of acetylcholinesterase (AChE) in bovine brain,Confirmatory,9871563.0,
15,30679,9,2,,103172342,3152,Active,,,0.008,IC50,Compound was evaluated for the inhibition of acetylcholinesterase (AChE) in bovine erythrocytes,Confirmatory,9871563.0,
16,30826,8,5,,103172342,3152,Active,14916950.0,540446.0,0.0029,Ki,Inhibition of fetal Bovine serum AChE,Confirmatory,12502352.0,
17,30867,8,5,,103172342,3152,Active,14916521.0,,0.0092,IC50,Inhibition of acetylcholinesterase (AChE) in electric eel (type V-S) by modified radiometric assay,Confirmatory,,
18,30868,11,2,,103172342,3152,Active,14916521.0,,0.048,IC50,In vitro inhibition of electric eel acetylcholinesterase,Confirmatory,11495583.0,
19,31010,9,5,,103172342,3152,Active,543754.0,,0.048,IC50,In vitro inhibition of Torpedo californica acetylcholinesterase.,Confirmatory,10052979.0,
20,31021,11,1,,103172342,3152,Active,,,0.008,IC50,Evaluated for the in vitro inhibition of the Acetylcholinesterase (AChE) from human erythrocytes,Confirmatory,8064800.0,
21,31023,9,2,,103172342,3152,Active,,,0.008,IC50,Compound was evaluated for the inhibition of acetylcholinesterase (AChE) in human erythrocytes,Confirmatory,9871563.0,
22,31035,7,1,,103172342,3152,Active,,,0.008,IC50,Concentration required to inhibit 50% of Acetylcholinesterase obtained from human erythrocytes was determined in vitro,Confirmatory,7707311.0,
23,31036,9,2,,103172342,3152,Active,,,0.018000000000000002,IC50,In vitro inhibition of human recombinant AChE.,Confirmatory,12182861.0,
24,31163,7,2,,103172342,3152,Active,,,0.022000000000000002,IC50,Ex vivo inhibition of human erythrocyte Acetylcholinesterase.,Confirmatory,12166941.0,
25,31170,8,5,,103172342,3152,Active,113037.0,43.0,0.00233,IC50,Inhibition of acetylcholinesterase (AChE) of human red blood cell (type XIII) by modified radiometric AChE assay,Confirmatory,,
26,31171,8,5,,103172342,3152,Active,113037.0,43.0,0.016,IC50,In vitro inhibition of acetylcholinesterase from human erythrocytes,Confirmatory,11495583.0,
27,31500,9,5,,103172342,3152,Active,113037.0,43.0,0.016,IC50,Inhibitory concentration against acetylcholinesterase (AChE) from human erythrocytes,Confirmatory,10052979.0,
28,31502,7,2,,103172342,3152,Active,,,0.0231,IC50,Inhibitory potency was evaluated against recombinant human AChE,Confirmatory,12773032.0,
29,31621,7,2,,103172342,3152,Active,,,0.0205,Ki,Inhibitory potency was evaluated against recombinant human AChE,Confirmatory,12773032.0,
30,31627,7,2,,103172342,3152,Active,,,0.008,IC50,Inhibition against Acetylcholinesterase (AChE),Confirmatory,8558505.0,
31,31777,3,6,,103172342,3152,Unspecified,,,,,Tested for inhibition of AChE-induced Abeta aggregation in the peripheral sites of the human enzyme at a concentration of 100 uM,Other,12773032.0,
32,31936,3,8,,103172342,3152,Unspecified,,,,,Acetylcholinesterase (AChE) enzyme was inhibited after 4 hr oral administration of 5 mg/kg of compound in rat brain ex vivo assay; A - Inhibition observed,Other,,
33,31937,3,8,,103172342,3152,Unspecified,,,,,Acetylcholinesterase (AChE) enzyme was inhibited after 8 hr oral administration of 10 mg/kg of compound in rat brain ex vivo assay; A - Inhibition observed,Other,,
34,31964,7,2,,103172342,3152,Active,,,0.0017,IC50,In vitro inhibitory effect on rat Acetylcholinesterase,Confirmatory,7636858.0,
35,32098,9,1,,103172342,3152,Active,,,0.02,IC50,Inhibitory activity against Acetylcholinesterase (AChE) in rat brain hippocampal crude homogenate,Confirmatory,10612585.0,
36,32101,7,2,,103172342,3152,Active,,,0.0057,IC50,Inhibitory concentration in vitro and ex vivo for anti-AChE activity in rat brain,Confirmatory,,
37,32111,5,5,,103172342,3152,Unspecified,,,,,Ex vitro inhibitory activity against acetylcholinesterase in rat brain after 1-30 mg/kg peritoneal administration of the compound; active,Other,1738151.0,
38,32285,9,2,,103172342,3152,Active,,,0.04,IC50,Inhibitory concentration required against acetylcholinesterase activity,Confirmatory,11689088.0,
39,44133,8,5,,103172342,3152,Active,75074633.0,,0.64,Ki,Inhibition of Equine Butyrylcholinesterase,Confirmatory,12502352.0,
40,44284,7,2,,103172342,3152,Active,,,2.9,IC50,Concentration required to inhibit 50% of Butyrylcholinesterase obtained from human serum was determined in vitro,Confirmatory,7707311.0,
41,44285,7,3,,103172342,3152,Active,,,4.15,IC50,Ex vivo inhibition of human plasma Butyrylcholinesterase.,Confirmatory,12166941.0,
42,44288,8,5,,103172342,3152,Active,116353.0,590.0,8.2,IC50,Inhibition of butyrylcholinesterase from human serum,Confirmatory,11495583.0,
43,44294,9,2,,103172342,3152,Active,,,8.2,IC50,Inhibitory concentration against Butyrylcholinesterase (BuChE) from human serum,Confirmatory,10052979.0,
44,44295,7,2,,103172342,3152,Active,,,7.42,IC50,Inhibitory potency was evaluated against isolated Butyrylcholinesterase,Confirmatory,12773032.0,
45,44442,7,3,,103172342,3152,Active,,,7.138,IC50,Inhibitory concentration was determined in in vitro for Butyrylcholinesterase in rat plasma,Confirmatory,,
46,44452,8,5,,103172342,3152,Active,75074633.0,,2.9,IC50,Compound was evaluated for the in vitro inhibition of the Butyrylcholinesterase from horse serum,Confirmatory,8064800.0,
47,44453,8,5,,103172342,3152,Active,75074633.0,,4.1667,IC50,Inhibition of (BChE) Butyrylcholinesterase of horse serum,Confirmatory,,
48,47966,7,2,,103172342,3152,Unspecified,,,,,Effective dose required for the reversal of vecuronium-induced neuromuscular block in-vivo in Chloaralose anaesthetised cats,Other,12182861.0,
49,48158,3,4,,103172342,3152,Unspecified,,,,,Change in heart rate was detected in anaesthetised cats on administration of the compound,Other,12182861.0,
50,48700,4,3,,103172342,3152,Unspecified,,,,,Mean arterial pressure change was detected in anaesthetised cats on administration of the compound,Other,12182861.0,
51,48731,3,4,,103172342,3152,Unspecified,,,,,Maximum reversal of vecuronium-induced neuromuscular block in-vivo in anaesthetised cats,Other,12182861.0,
52,49085,3,3,,103172342,3152,Unspecified,,,,,Change in response to vagal stimulation was detected in anaesthetised cats on administration of the compound,Other,12182861.0,
53,73711,6,3,,103172342,3152,Active,,,0.043,EC50,In vitro reversal of vecuronium-induced neuromuscular block in guinea pig hemi-diaphragm.,Confirmatory,12182861.0,
54,131755,6,2,,103172342,3152,Unspecified,,,,,Tested for effective dose for elevation of Acetylcholinesterase (AChE) in mouse forebrain,Other,8064800.0,
55,227060,3,6,,103172342,3152,Unspecified,,,,,IC50 (hBuChE/hAChE) ratio of the compound,Other,11495583.0,
56,229541,3,7,,103172342,3152,Unspecified,,,,,Ratio of IC50 values of BuChE / AChE activity,Other,,
57,230724,3,6,,103172342,3152,Unspecified,,,,,Ratio of the IC50 values of BuChE and AcHe,Other,8064800.0,
58,232649,3,3,,103172342,3152,Unspecified,,,,,Ratio of inhibitory activity of ocmpound towards acetylcholinesterase from human erythrocytes over acetylcholinesterase from human serum,Other,10052979.0,
59,234643,3,9,,103172342,3152,Unspecified,113037.0,43.0,,,Selectivity at AChE and BChE,Other,12166941.0,
60,234643,3,9,,103172342,3152,Unspecified,116353.0,590.0,,,Selectivity at AChE and BChE,Other,12166941.0,
61,238665,9,1,,103172342,3152,Active,14916950.0,540446.0,0.0029,Ki,Dissociation constant for inhibition of fetal bovine serum Acetylcholinesterase,Confirmatory,15771436.0,
62,238704,8,1,,103172342,3152,Active,75074633.0,,0.64,Ki,Dissociation constant for inhibition of equine Butyrylcholinesterase (BuChE),Confirmatory,15771436.0,
63,241560,8,5,,103172342,3152,Active,116353.0,590.0,4.15,IC50,Inhibitory concentration against human plasma Butyrylcholinesterase,Confirmatory,15715468.0,
64,241692,8,5,,103172342,3152,Active,113037.0,43.0,0.022000000000000002,IC50,Inhibitory concentration against human erythrocyte Acetylcholinesterase,Confirmatory,15715468.0,
65,241886,10,1,,103172342,3152,Active,81917534.0,,7.6,IC50,In vitro inhibitory concentration against butyrylcholinesterase was determined using rat serum homogenate,Confirmatory,15993600.0,
66,242428,10,1,,103172342,3152,Active,584716.0,83817.0,0.016,IC50,In vitro inhibitory concentration against rat cortex acetylcholinesterase,Confirmatory,15993600.0,
67,262754,8,5,,103172342,3152,Active,113037.0,43.0,0.022000000000000002,IC50,Anticholinesterase activity against human erythrocyte AChE,Confirmatory,16570913.0,
68,262755,8,5,,103172342,3152,Active,116353.0,590.0,4.15,IC50,Anticholinesterase activity against human plasma BChE,Confirmatory,16570913.0,
69,262756,3,9,,103172342,3152,Unspecified,113037.0,43.0,,,Selectivity for AChE over BChE,Other,16570913.0,
70,262756,3,9,,103172342,3152,Unspecified,116353.0,590.0,,,Selectivity for AChE over BChE,Other,16570913.0,
71,282007,10,4,,103172342,3152,Active,113037.0,43.0,,IC50,Inhibition of human recombinant AChE,Confirmatory,15588084.0,
72,282008,7,4,,103172342,3152,Active,116353.0,590.0,7.585780000000001,IC50,Inhibition of human recombinant BChE,Confirmatory,15588084.0,
73,282009,3,9,,103172342,3152,Unspecified,113037.0,43.0,,,Selectivity for human BChE over human AChE,Other,15588084.0,
74,282009,3,9,,103172342,3152,Unspecified,116353.0,590.0,,,Selectivity for human BChE over human AChE,Other,15588084.0,
75,282010,3,7,,103172342,3152,Inconclusive,,,,,Antagonist activity at muscarinic M2 receptor assessed as contraction of electrically stimulated guinea pig left atrium at 10 uM,Other,15588084.0,
76,282011,5,8,,103172342,3152,Unspecified,113037.0,43.0,,,Inhibition of AChE mediated aggregation of amyloid beta relative to control,Other,15588084.0,
77,282830,7,6,,103172342,3152,Inconclusive,113037.0,43.0,,IC50,Inhibition of human AChE-induced beta amyloid peptide(1-40) aggregation by thioflavin T-based fluorometric assay,Confirmatory,16279781.0,
78,282831,5,6,,103172342,3152,Unspecified,113037.0,43.0,,,Inhibition of beta amyloid protein 40 aggregation at 100 uM by thioflavin T-based fluorometric assay,Other,16279781.0,
79,289392,9,5,,103172342,3152,Active,116353.0,590.0,10.05,IC50,Inhibition of human BChE by Ellman's method,Confirmatory,17681794.0,
80,289393,3,3,,103172342,3152,Unspecified,,,,,Selectivity for Electrophorus electricus AChE over human BchE,Other,17681794.0,
81,289395,6,2,,103172342,3152,Unspecified,,,86.5,IC50,Inhibition of beta amyloid protein 1-42 aggregation by thioflavin T assay,Confirmatory,17681794.0,
82,289396,5,8,,103172342,3152,Unspecified,14916521.0,,,,Inhibition of Electrophorus electricus AchE-induced beta amyloid protein 1-42 co-aggregation at 100 uM by thioflavin T assay,Other,17681794.0,
83,289397,5,8,,103172342,3152,Unspecified,14916521.0,,,,Inhibition of Electrophorus electricus AchE-induced beta amyloid protein 1-42 co-aggregation at 1 uM by thioflavin T assay,Other,17681794.0,
84,289398,3,4,,103172342,3152,Unspecified,,,,,Neuroprotective effect against beta amyloid protein 1-42 treated human IMR32 cells at 0.1 umol/ml after 48 hrs by MTT assay,Other,17681794.0,
85,298278,8,5,,103172342,3152,Active,113037.0,43.0,0.0231,IC50,Inhibition of human recombinant acetylcholinesterase,Confirmatory,17850125.0,
86,298279,8,5,,103172342,3152,Active,116353.0,590.0,7.42,IC50,Inhibition of human recombinant butyrylcholinesterase,Confirmatory,17850125.0,
87,298281,3,4,,103172342,3152,Unspecified,112927.0,351.0,,,Inhibition of self-induced amyloid beta (1-40) aggregation at 10 uM by thioflavin T based fluorometric assay,Other,17850125.0,
88,311932,3,10,,103172342,3152,Unspecified,224471897.0,6609.0,,,Inhibition of ASM in human H4 cells assessed as residual activity at 10 uM,Other,18027916.0,
89,311934,3,3,,103172342,3152,Unspecified,,,,,"Dissociation constant, pKa of the compound",Other,18027916.0,
90,314091,11,2,,103172342,3152,Active,113037.0,43.0,0.023,IC50,Inhibition of human AchE,Confirmatory,18181565.0,
91,314093,3,9,,103172342,3152,Unspecified,113037.0,43.0,,,Inhibition of human AchE-induced amyloid beta aggregation at 100 uM,Other,18181565.0,
92,323564,7,2,,103172342,3152,Active,,,0.16,IC50,Inhibition of AChE,Confirmatory,18249544.0,
93,323565,7,3,,103172342,3152,Active,,,0.35,IC50,Inhibition of histamine H3 receptor,Confirmatory,18249544.0,
94,345205,8,5,,103172342,3152,Active,113037.0,43.0,0.0231,IC50,Inhibition of human recombinant AChE by Ellman's assay,Confirmatory,18954037.0,
95,345206,8,5,,103172342,3152,Active,116353.0,590.0,7.42,IC50,Inhibition of human serum BChE by Ellman's assay,Confirmatory,18954037.0,
96,345207,3,9,,103172342,3152,Unspecified,113037.0,43.0,,,Inhibition of human recombinant AChE-induced amyloid beta (1-40) aggregation at 100 uM by thioflavin T formation assay,Other,18954037.0,
97,345208,3,8,,103172342,3152,Unspecified,,,,,Inhibition of self-induced amyloid beta (1-40) aggregation at 10 uM by thioflavin T formation assay,Other,18954037.0,
98,349883,3,3,,103172342,3152,Inactive,,,,,Inhibition of amyloid beta (1-42) self-aggregation at 50 uM after 24 hrs by thioflavin T fluorescence method,Other,19374444.0,
99,351914,9,5,,103172342,3152,Active,113037.0,43.0,0.02,IC50,Inhibition of human recombinant AChE by Ellman's method,Confirmatory,18396354.0,
100,351915,9,5,,103172342,3152,Active,116353.0,590.0,7.42,IC50,Inhibition of human serum BChE by Ellman's method,Confirmatory,18396354.0,
101,351916,3,3,,103172342,3152,Unspecified,,,,,"Selectivity ratio, IC50 for human serum BChE to IC50 for human recombinant AChE",Other,18396354.0,
102,361789,8,5,,103172342,3152,Active,584716.0,83817.0,0.0268,IC50,Inhibition of AchE in rat cortex by Ellman's method,Confirmatory,18662884.0,
103,361790,8,5,,103172342,3152,Active,81917534.0,,3.26,IC50,Inhibition of BuchE in rat serum by Ellman's method,Confirmatory,18662884.0,
104,361791,3,4,,103172342,3152,Unspecified,,,,,Selectivity ratio of IC50 for BuchE in rat serum to IC50 for AchE in rat cortex,Other,18662884.0,
105,361792,3,4,,103172342,3152,Active,,,,,Neuroprotective activity in rat PC12 cells assessed as inhibition of H2O2-induced neurotoxicity at 0.1 uM after 2 hrs by MTT assay,Other,18662884.0,
106,361793,3,4,,103172342,3152,Active,,,,,Neuroprotective activity against rat PC12 cells assessed as inhibition of H2O2-induced neurotoxicity at 0.5 uM after 2 hrs by MTT assay,Other,18662884.0,
107,364670,9,5,,103172342,3152,Active,14916521.0,,0.11,IC50,Inhibition of Electrophorus electricus brain AChE by Ellman's method,Confirmatory,18701305.0,
108,384079,11,2,,103172342,3152,Active,21362409.0,100033901.0,2.7,IC50,Inhibition of horse serum butyrylcholine esterase in presence of acetylcholine substrate by chemiluminescent assay,Confirmatory,17624631.0,
109,384080,11,2,,103172342,3152,Active,584716.0,83817.0,0.04,IC50,Inhibition of rat brain acetylcholine esterase in presence of acetylcholine substrate by chemiluminescent assay,Confirmatory,17624631.0,
110,384081,11,2,,103172342,3152,Active,81917534.0,,5.3,IC50,Inhibition of rat plasma butyrylcholine esterase in presence of butyrylcholine substrate by chemiluminescent assay,Confirmatory,17624631.0,
111,388546,8,5,,103172342,3152,Active,584716.0,83817.0,0.035480000000000005,IC50,Inhibition of acetylcholinesterase in Wistar rat brain homogenate by Ellman's method,Confirmatory,18976927.0,
112,392812,3,10,,103172342,3152,Unspecified,296434407.0,23621.0,,,Inhibition of human recombinant C-terminal histidine-tagged BACE1 expressed in baculovirus-infected insect cells at 50 ug/mL by FRET assay,Other,19162488.0,
113,392814,11,2,,103172342,3152,Active,584716.0,83817.0,0.007859999999999999,IC50,Inhibition of AChE in rat cortex preincubated for 20 mins by Ellman method,Confirmatory,19162488.0,
114,395657,9,5,,103172342,3152,Active,584716.0,83817.0,0.012,IC50,Inhibition of AChE in rat cortex after 15 mins by modified Ellman method,Confirmatory,18436348.0,
115,395658,9,5,,103172342,3152,Active,81917534.0,,2.77,IC50,Inhibition of BChE in rat serum after 15 mins by modified Ellman method,Confirmatory,18436348.0,
116,395659,3,4,,103172342,3152,Unspecified,,,,,Selectivity ratio of IC50 for BChE in rat serum to IC50 for AChE in rat cortex,Other,18436348.0,
117,395660,3,3,,103172342,3152,Unspecified,,,,,"Cognitive enhancing effect against scopolamine-induced acquisition memory deficit in mouse assessed as times of step-down at 2 mg/kg, intragastric gavage after 24 hrs by step-down passive avoidance test",Other,18436348.0,
118,395663,3,3,,103172342,3152,Unspecified,,,,,"Cognitive enhancing effect against scopolamine-induced acquisition memory deficit in mouse assessed as escape latency at 2 mg/kg, intragastric gavage after 24 hrs by step-down passive avoidance test",Other,18436348.0,
119,404842,8,5,,103172342,3152,Active,14916950.0,540446.0,0.019,IC50,Inhibition of bovine erythrocyte AChE by Ellman's assay,Confirmatory,18517184.0,
120,404844,8,5,,103172342,3152,Active,116353.0,590.0,0.93,IC50,Inhibition of human serum BChE by Ellman's assay,Confirmatory,18517184.0,
121,404845,8,5,,103172342,3152,Active,584716.0,83817.0,0.0057,IC50,Inhibition of rat cortex AChE,Confirmatory,18517184.0,
122,404846,8,5,,103172342,3152,Active,81917534.0,,7.138,IC50,Inhibition of rat serum BChE,Confirmatory,18517184.0,
123,454342,8,5,,103172342,3152,Active,584716.0,83817.0,0.012,IC50,Inhibition of AChE in rat cortex after 15 mins by modified Ellman's method,Confirmatory,19692250.0,
124,454343,8,5,,103172342,3152,Active,81917534.0,,4.67,IC50,Inhibition of BChE in rat serum after 15 mins by modified Ellman's method,Confirmatory,19692250.0,
125,454344,3,4,,103172342,3152,Unspecified,,,,,Selectivity ratio of IC50 for BChE in rat serum to IC50 for AChE in rat cortex,Other,19692250.0,
126,462782,8,5,,103172342,3152,Active,113037.0,43.0,0.02,IC50,Inhibition of human recombinant AChE preincubated for 20 mins before substrate addition by Ellman's method,Confirmatory,20171894.0,
127,462783,8,5,,103172342,3152,Active,116353.0,590.0,7.42,IC50,Inhibition of human BuChE preincubated for 20 mins before substrate addition by Ellman's method,Confirmatory,20171894.0,
128,462784,3,3,,103172342,3152,Unspecified,,,,,Selectivity ratio of IC50 for human BuChE to human recombinant AChE,Other,20171894.0,
129,462787,3,3,,103172342,3152,Unspecified,,,,,Inhibition of amyloid beta (1-42) self-aggregation at 10 uM after 24 hrs by thioflavin T-based fluorometric assay,Other,20171894.0,
130,462788,3,9,,103172342,3152,Unspecified,113037.0,43.0,,,Inhibition of human recombinant AChE-induced amyloid beta (1-40) aggregation at 100 uM after 48 hrs by thioflavin T fluorescence spectroscopy,Other,20171894.0,
131,469245,8,5,,103172342,3152,Active,14916521.0,,0.12,IC50,Inhibition of Electrophorus electricus AChE by Ellman's method,Confirmatory,19643609.0,
132,482853,5,2,,103172342,3152,Unspecified,,,62.7,IC50,Selectivity ratio of IC50 for equine serum BuChE to IC50 for electric eel AChE,Confirmatory,20575555.0,
133,482854,8,5,,103172342,3152,Active,21362409.0,100033901.0,0.84,IC50,Inhibition of equine serum BuChE by Ellman's method,Confirmatory,20575555.0,
134,482855,8,5,,103172342,3152,Active,113037.0,43.0,0.0082,IC50,Inhibition of AChE in human erythrocytes by Ellman's method,Confirmatory,20575555.0,
135,482856,8,5,,103172342,3152,Active,14916521.0,,0.0134,IC50,Inhibition of electric eel AChE by Ellman's method,Confirmatory,20575555.0,
136,482894,7,2,,103172342,3152,Active,,,0.008,IC50,Inhibition of AChE,Confirmatory,20053484.0,
137,492961,1,1,,50112790,3152,Inactive,72386991.0,3656265.0,,Potency,qHTS Assay to Find Inhibitors of T. brucei phosphofructokinase: hit validation,Confirmatory,,
138,493017,1,1,,103853425,3152,Active,,43.0,,,Wombat Data for BeliefDocking,Other,15588084.0,
139,496881,8,2,,103172342,3152,Active,,,,IC50,Inhibition of AChE,Confirmatory,20420456.0,
140,496882,7,2,,103172342,3152,Unspecified,,,100.0,IC50,Inhibition of AChE-induced amyloid beta (1-40) aggregation,Confirmatory,20420456.0,
141,504327,1,1,,50112790,3152,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
142,504332,1,1,,50112790,3152,Inconclusive,168985070.0,,6.3096,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
143,504749,1,3,,50112790,3152,Unspecified,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
144,504749,1,3,1.0,50112790,3152,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
145,504749,1,3,2.0,50112790,3152,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
146,504749,1,3,3.0,50112790,3152,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
147,504749,1,3,4.0,50112790,3152,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
148,504749,1,3,5.0,50112790,3152,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
149,504749,1,3,6.0,50112790,3152,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
150,504749,1,3,7.0,50112790,3152,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
151,504749,1,3,8.0,50112790,3152,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
152,504749,1,3,9.0,50112790,3152,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
153,504749,1,3,10.0,50112790,3152,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
154,504749,1,3,11.0,50112790,3152,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
155,504749,1,3,12.0,50112790,3152,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
156,504749,1,3,13.0,50112790,3152,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
157,504749,1,3,14.0,50112790,3152,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
158,504749,1,3,15.0,50112790,3152,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
159,504749,1,3,16.0,50112790,3152,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
160,504749,1,3,17.0,50112790,3152,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
161,504749,1,3,18.0,50112790,3152,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
162,504749,1,3,19.0,50112790,3152,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
163,504749,1,3,20.0,50112790,3152,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
164,504749,1,3,21.0,50112790,3152,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
165,504749,1,3,22.0,50112790,3152,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
166,504749,1,3,23.0,50112790,3152,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
167,504749,1,3,24.0,50112790,3152,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
168,504749,1,3,25.0,50112790,3152,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
169,504749,1,3,26.0,50112790,3152,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
170,504749,1,3,27.0,50112790,3152,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
171,504749,1,3,28.0,50112790,3152,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
172,504749,1,3,29.0,50112790,3152,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
173,504749,1,3,30.0,50112790,3152,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
174,504749,1,3,31.0,50112790,3152,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
175,504749,1,3,32.0,50112790,3152,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
176,504749,1,3,33.0,50112790,3152,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
177,504749,1,3,34.0,50112790,3152,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
178,504749,1,3,35.0,50112790,3152,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
179,504749,1,3,36.0,50112790,3152,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
180,504749,1,3,37.0,50112790,3152,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
181,504749,1,3,38.0,50112790,3152,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
182,504749,1,3,39.0,50112790,3152,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
183,504749,1,3,40.0,50112790,3152,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
184,504749,1,3,41.0,50112790,3152,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
185,504749,1,3,42.0,50112790,3152,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
186,504749,1,3,43.0,50112790,3152,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
187,504749,1,3,44.0,50112790,3152,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
188,504749,1,3,45.0,50112790,3152,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
189,504749,1,3,46.0,50112790,3152,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
190,504749,1,3,47.0,50112790,3152,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
191,504749,1,3,48.0,50112790,3152,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
192,504749,1,3,49.0,50112790,3152,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
193,504749,1,3,50.0,50112790,3152,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
194,504749,1,3,51.0,50112790,3152,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
195,504749,1,3,52.0,50112790,3152,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
196,504749,1,3,53.0,50112790,3152,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
197,504749,1,3,54.0,50112790,3152,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
198,504749,1,3,55.0,50112790,3152,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
199,504749,1,3,56.0,50112790,3152,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
200,504749,1,3,57.0,50112790,3152,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
201,504749,1,3,58.0,50112790,3152,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
202,504749,1,3,59.0,50112790,3152,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
203,504749,1,3,60.0,50112790,3152,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
204,504749,1,3,61.0,50112790,3152,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
205,504832,1,1,,50112790,3152,Inconclusive,,,10.690999999999999,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation",Confirmatory,,
206,504834,1,1,,50112790,3152,Active,,,9.5283,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation",Confirmatory,,
207,504847,1,1,,50112790,3152,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
208,504865,1,1,,50112790,3152,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Pilot qHTS,Confirmatory,,
209,511766,6,5,,103172342,3152,Active,113037.0,43.0,0.09,IC50,Inhibition of human AChE by Ellmans test,Confirmatory,20684567.0,
210,511767,2,3,,103172342,3152,Unspecified,,,,,"Antidementia against scopolamine-induced cognitive impairment in Swiss albino mouse assessed as improvement in latency to transfer from bright to dark compartment at 20 umol/kg, po by passive avoidance test",Other,20684567.0,
211,538478,7,5,,103172342,3152,Active,113037.0,43.0,0.12,IC50,Inhibition of human acetyl cholinesterase by Ellmann's method,Confirmatory,20951037.0,
212,539464,4,2,,103172342,3152,Unspecified,,,,,Solubility of the compound in 0.1 M phosphate buffer at 600 uM at pH 7.4 after 24 hrs by LC/MS/MS analysis,Other,21055935.0,
213,540235,1,3,,103172342,3152,Inactive,,,,,Phospholipidosis-negative literature compound,Other,17428028.0,
214,576612,7,5,,103172342,3152,Active,7531135.0,3757.0,1.9952599999999998,IC50,Inhibition of human ERG,Confirmatory,21185626.0,
215,588208,2,3,,103172342,3152,Unspecified,,,,,Literature-mined public compounds from Lowe et al phospholipidosis modelling dataset,Other,20799726.0,
216,588209,2,3,,103172342,3152,Unspecified,,,,,Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset,Other,20553011.0,
217,588210,2,4,,103172342,3152,Unspecified,,,,,Human drug-induced liver injury (DILI) modelling dataset from Ekins et al,Other,20843939.0,
218,588579,1,1,,50112790,3152,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
219,594820,4,2,,103172342,3152,Active,,,0.006,IC50,Inhibition of AChE-induced amyloid beta aggregation,Confirmatory,21216144.0,
220,594821,5,1,,103172342,3152,Active,,,7.0,IC50,Inhibition of BChE,Confirmatory,21216144.0,
221,594989,5,5,,103172342,3152,Active,113037.0,43.0,0.018000000000000002,IC50,Inhibition of human recombinant AChE after 20 mins using acetylthiocholine iodide as a substrate by Ellman's assay,Confirmatory,21417225.0,
222,594990,5,5,,103172342,3152,Active,116353.0,590.0,3.9,IC50,Inhibition of human BChE after 20 mins using butyrylthiocholine iodide as a substrate by Ellman's assay,Confirmatory,21417225.0,
223,594991,2,3,,103172342,3152,Inactive,,,,,Inhibition of amyloid beta (1-40) aggregation at 100 uM by thioflavin-T based spectrofluorometric assay,Other,21417225.0,
224,595289,6,5,,103172342,3152,Active,113037.0,43.0,0.023,IC50,Inhibition of human AChE using acetylthiocholine iodide as substrate by Ellman's assay,Confirmatory,21397996.0,
225,595290,6,5,,103172342,3152,Active,116353.0,590.0,7.4,IC50,Inhibition of human BChE using butyrylthiocholine iodide as substrate by Ellman's method,Confirmatory,21397996.0,
226,595291,1,5,,103172342,3152,Unspecified,,,,,Selectivity ratio of IC50 for human BChE to IC50 for human AChE,Other,21397996.0,
227,595292,2,9,,103172342,3152,Unspecified,113037.0,43.0,,,Inhibition of human AChE-induced beta-amyloid (1-40) aggregation at 100 uM by thioflavin-T based fluorimetric assay,Other,21397996.0,
228,600978,9,2,,103172342,3152,Active,113037.0,43.0,0.022000000000000002,IC50,Inhibition of human erythrocytes AChE,Confirmatory,21459491.0,
229,600979,9,2,,103172342,3152,Active,113037.0,43.0,0.022000000000000002,IC50,Inhibition of human plasma AChE,Confirmatory,21459491.0,
230,600980,8,2,,103172342,3152,Active,113037.0,43.0,4.15,IC50,Inhibition of human erythrocytes BChE,Confirmatory,21459491.0,
231,600981,8,2,,103172342,3152,Active,113037.0,43.0,4.15,IC50,Inhibition of human plasma BChE,Confirmatory,21459491.0,
232,602332,1,1,,50112790,3152,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
233,624030,1,2,,50112790,3152,Inactive,160794.0,,,Potency,Biochemical firefly luciferase enzyme assay for NPC,Confirmatory,,
234,624031,1,2,,50112790,3152,Inconclusive,,,40.5334,Potency,S16 Schwann cell viability assay (CellTiter-Glo assay),Confirmatory,,
235,624032,1,2,,50112790,3152,Inconclusive,8393992.0,24660.0,10.1815,Potency,S16 Schwann cell PMP22 intronic element firefly luciferase assay,Confirmatory,,
236,624044,1,2,,50112790,3152,Inactive,8393992.0,24660.0,,Potency,S16 Schwann cell PMP22 intronic element beta-lactamase assay,Confirmatory,,
237,624170,1,1,,50112790,3152,Inactive,71051501.0,2744.0,,Potency,qHTS for Inhibitors of Glutaminase (GLS),Confirmatory,,
238,624172,1,1,,50112790,3152,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists,Confirmatory,,
239,624173,1,3,,50112790,3152,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors,Confirmatory,,
240,624296,1,1,,50112790,3152,Inconclusive,7705682.0,51053.0,37.5857,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,Confirmatory,,
241,624297,1,1,,50112790,3152,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,Confirmatory,,
242,625279,1,3,,103172342,3152,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia,Other,22194678.0,
243,625280,1,3,,103172342,3152,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis,Other,22194678.0,
244,625281,1,3,,103172342,3152,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis,Other,22194678.0,
245,625282,1,3,,103172342,3152,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis,Other,22194678.0,
246,625283,1,3,,103172342,3152,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests,Other,22194678.0,
247,625284,1,3,,103172342,3152,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure,Other,22194678.0,
248,625285,1,3,,103172342,3152,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis,Other,22194678.0,
249,625286,1,3,,103172342,3152,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis,Other,22194678.0,
250,625287,1,3,,103172342,3152,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly,Other,22194678.0,
251,625288,1,3,,103172342,3152,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice,Other,22194678.0,
252,625289,1,3,,103172342,3152,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease,Other,22194678.0,
253,625290,1,3,,103172342,3152,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty,Other,22194678.0,
254,625291,1,3,,103172342,3152,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal,Other,22194678.0,
255,625292,1,3,,103172342,3152,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score,Other,22194678.0,
256,635810,7,2,,103172342,3152,Active,584716.0,83817.0,0.005,IC50,Inhibition of AChE in rat cortex homogenates using acetylthiocholine iodide as substrate after 15 mins by Ellman's method,Confirmatory,22019465.0,
257,635811,1,5,,103172342,3152,Inconclusive,,,,,Antagonist activity at histamine H3 receptor expressed in HEK293 cells co-transfected with pCRE-Luc gene assessed as inhibition of forskolin/histamine-induced cAMP accumulation at 1 uM after 5 hrs by luciferase reporter gene assay,Other,22019465.0,
258,635813,1,5,,103172342,3152,Inconclusive,,,,IC50,Inverse agonist activity at histamine H3 receptor expressed in HEK293 cells co-transfected with pCRE-Luc gene assessed as inhibition of forskolin/histamine-induced cAMP accumulation after 5 hrs by luciferase reporter gene assay,Confirmatory,22019465.0,
259,635814,1,6,,103172342,3152,Inconclusive,,,,,Inhibition of BACE1 at 20 ug/mL by FRET assay,Other,22019465.0,
260,635870,5,5,,103172342,3152,Active,14916521.0,,0.0067,IC50,Inhibition of Electrophorus electricus AchE using acetylthiocholine iodide as substrate preincubated for 10 mins measured after 15 mins of substrate addition by Ellman's method,Confirmatory,22023459.0,
261,635871,5,5,,103172342,3152,Active,21362409.0,100033901.0,7.4,IC50,Inhibition of equine serum BuchE using butyrylthiocholine iodide as substrate preincubated for 10 mins measured after 15 mins of substrate addition by Ellman's method,Confirmatory,22023459.0,
262,635872,1,4,,103172342,3152,Unspecified,,,,,Selectivity ratio of IC50 for equine serum BuchE to IC50 for Electrophorus electricus AchE,Other,22023459.0,
263,635877,4,5,,103172342,3152,Unspecified,113979.0,29253.0,850.0,IC50,Inhibition of rat liver mitochondrial MAO-A using [14C]-5-hydroxytryptamine after 30 mins by scintillation counting,Confirmatory,22023459.0,
264,635878,4,5,,103172342,3152,Active,124028639.0,25750.0,15.0,IC50,Inhibition of rat liver mitochondrial MAO-B using [14C]-phenylethylamine after 30 mins by scintillation counting,Confirmatory,22023459.0,
265,635879,1,4,,103172342,3152,Unspecified,,,,,Selectivity ratio of IC50 for rat liver mitochondrial MAO-B to IC50 for rat liver mitochondrial MAO-A,Other,22023459.0,
266,635890,1,9,,103172342,3152,Unspecified,113037.0,43.0,,,Inhibition of human AChE-induced amyloid beta (1 to 40) aggregation,Other,22023459.0,
267,657793,1,4,,103172342,3152,Unspecified,,,,,Selectivity ratio of IC50 for mitochondrial MAO-B in rat liver homogenates to IC50 for mitochondrial MAO-A in rat liver homogenates,Other,22503231.0,
268,657795,7,2,,103172342,3152,Active,124028639.0,25750.0,15.0,IC50,Inhibition of mitochondrial MAO-B in rat liver homogenates using [14C]-phenylethylamine as substrate preincubated for 30 mins by liquid scintillation counting,Confirmatory,22503231.0,
269,657796,7,2,,103172342,3152,Unspecified,113979.0,29253.0,850.0,IC50,Inhibition of mitochondrial MAO-A in rat liver homogenates using [14C]-(5-hydroxy-triptamine) as substrate preincubated for 30 mins by liquid scintillation counting,Confirmatory,22503231.0,
270,658003,1,3,,103172342,3152,Unspecified,,,,,Selectivity ratio of IC50 for equine serum BChE to IC50 for electric eel AChE,Other,22503231.0,
271,658004,5,5,,103172342,3152,Active,75074633.0,,7.4,IC50,Inhibition of equine serum BChE using butyrylthiocholine iodide as substrate after 15 mins by Ellman's method,Confirmatory,22503231.0,
272,658005,5,5,,103172342,3152,Active,14916521.0,,0.0067,IC50,Inhibition of electric eel AChE using acetylthiocholine iodide as substrate after 15 mins by Ellman's method,Confirmatory,22503231.0,
273,666573,5,5,,103172342,3152,Active,14916521.0,,0.026000000000000002,IC50,Inhibition of electric eel acetylcholine esterase using acetylcholine chloride as substrate incubated for 15 mins prior to substrate addition measured every 1 min by Ellman's assay,Confirmatory,22633691.0,
274,666575,5,5,,103172342,3152,Active,21362409.0,100033901.0,4.66,IC50,Inhibition of equine serum butyrylcholinesterase using butyrylthiocholine chloride as substrate incubated for 15 mins prior to substrate addition measured every 1 min by Ellman's assay,Confirmatory,22633691.0,
275,666578,1,3,,103172342,3152,Unspecified,,,,,Selectivity ratio of IC50 for equine serum butyrylcholinesterase to IC50 for electric eel acetylcholine esterase,Other,22633691.0,
276,670563,5,5,,103172342,3152,Active,113037.0,43.0,0.032,IC50,Inhibition of human AChE using acetylthiocholine iodide as substrate after 5 mins by DTNB method,Confirmatory,22704921.0,
277,670564,5,5,,103172342,3152,Active,21362409.0,100033901.0,3.6,IC50,Inhibition of equine BuChE using butyrylthiocholine iodide as substrate after 5 mins by DTNB method,Confirmatory,22704921.0,
278,670566,4,2,,103172342,3152,Active,,,3.2,IC50,Inhibition of BACE1,Confirmatory,22704921.0,
279,670569,1,3,,103172342,3152,Inconclusive,,,,,Inhibition of self-induced amyloid beta (1 to 40) aggregation at 100 uM after 24 hrs by thioflavin T-based fluorescence analysis,Other,22704921.0,
280,677013,4,5,,103172342,3152,Active,584716.0,83817.0,0.0215,IC50,Inhibition of AChE activity in rat brain homogenate using acetylthiocholine as substrate by Ellman's method,Confirmatory,22172310.0,
281,677019,1,3,,103172342,3152,Unspecified,,,,,"Antiamnesic activity in mouse assessed as inhibition of scopolamine-induced escape latency time at 25 mg/kg, ip measured on day 1 by Morris water maze test (Rvb = 89.7 +/- 3.8 secs)",Other,22172310.0,
282,677023,1,3,,103172342,3152,Unspecified,,,,,"Antiamnesic activity in mouse assessed as inhibition of scopolamine-induced escape latency time at 25 mg/kg, ip measured on day 4 by Morris water maze test (Rvb = 78.7 +/- 5.7 secs)",Other,22172310.0,
283,677026,1,3,,103172342,3152,Active,,,,,"Antiamnesic activity in scopolamine-induced amnesia mouse model assessed as increase in time spent in target quadrant at 25 mg/kg, ip measured on day 5 by Morris water maze test",Other,22172310.0,
284,678712,1,8,,103172342,3152,Inconclusive,117144.0,1544.0,,,Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins,Other,22931300.0,
285,678713,1,8,,103172342,3152,Inconclusive,6686268.0,1559.0,,,Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins,Other,22931300.0,
286,678714,1,8,,103172342,3152,Inconclusive,60416369.0,1557.0,,,Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins,Other,22931300.0,
287,678715,1,8,,103172342,3152,Inconclusive,84028191.0,1565.0,,,Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins,Other,22931300.0,
288,678716,1,8,,103172342,3152,Inconclusive,116241312.0,1576.0,,,Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins,Other,22931300.0,
289,678717,1,8,,103172342,3152,Inconclusive,116241312.0,1576.0,,,Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-benzyloxyquinoline as substrate after 30 mins,Other,22931300.0,
290,678722,1,5,,103172342,3152,Unspecified,,,,,Covalent binding affinity to human liver microsomes assessed per mg of protein at 10 uM after 60 mins presence of NADPH,Other,22931300.0,
291,682339,5,5,,103172342,3152,Active,113037.0,43.0,0.01,IC50,Inhibition of human erythrocyte AChE using acetylthiocholine as substrate by Ellman method,Confirmatory,23078965.0,
292,682340,5,5,,103172342,3152,Active,116353.0,590.0,2.5,IC50,Inhibition of human serum BChE using butyrylthiocholine as substrate by Ellman method,Confirmatory,23078965.0,
293,682359,1,3,,103172342,3152,Unspecified,,,,,"Selectivity index, ratio of IC50 for human serum BChE to IC50 for human erythrocyte AChE",Other,23078965.0,
294,695008,1,3,,103172342,3152,Active,,,,,"Antialzheimer activity in Kunming mouse assessed as reversal of amyloid beta (1 to 42)-induced impairments in spartial recognition memory at 0.65 mg/kg, po qd measured on day 3 and 4 by morris water maze test",Other,24900405.0,
295,695010,1,3,,103172342,3152,Active,,,,,"Antialzheimer activity in Kunming mouse assessed as reversal of amyloid beta (1 to 42)-induced decrease of swimming percentage of path length at 0.656 mg/kg, po qd measured on day 13 by morris water maze test",Other,24900405.0,
296,695012,1,3,,103172342,3152,Active,,,,,"Antialzheimer activity in Kunming mouse assessed as reversal of amyloid beta (1 to 42)-induced decrease of swimming time spent in target quadrant at 0.65 mg/kg, po qd measured on day 13 by morris water maze test",Other,24900405.0,
297,707697,1,8,,103172342,3152,Inactive,148887359.0,102414.0,,,Inhibition of mouse recombinant GST-tagged CLK3 expressed in Escherichia coli using GRSRSRSRSRSR as substrate and [gamma33P]ATP at 10 uM after 30 mins by scintillation counting,Other,22998443.0,
298,707698,1,8,,103172342,3152,Inactive,341940357.0,12747.0,,,Inhibition of mouse recombinant GST-tagged CLK1 expressed in Escherichia coli using GRSRSRSRSRSR as substrate and [gamma33P]ATP at 10 uM after 30 mins by scintillation counting,Other,22998443.0,
299,707699,1,8,,103172342,3152,Inactive,148887370.0,8445.0,,,Inhibition of human recombinant GST-tagged DYRK2 expressed in Escherichia coli using GRSRSRSRSRSR as substrate and [gamma33P]ATP at 10 uM after 30 mins by scintillation counting,Other,22998443.0,
300,707700,1,8,,103172342,3152,Inactive,3219996.0,1859.0,,,Inhibition of human recombinant GST-tagged DYRK1A expressed in Escherichia coli using GRSRSRSRSRSR as substrate and [gamma33P]ATP at 10 uM after 30 mins by scintillation counting,Other,22998443.0,
301,722584,2,5,,103172342,3152,Active,113037.0,43.0,0.0072,Ki,Inhibition of human erythrocyte AChE using acetylthiocholine iodide as substrate after 60 mins by Ellman's method,Confirmatory,23276831.0,
302,724165,2,5,,103172342,3152,Active,21362409.0,100033901.0,1.9,IC50,Inhibition of equine butyrylcholinesterase using butyrylthiocholine as substrate incubated for 20 mins prior to substrate addition measured after 3 mins by Ellman's method,Confirmatory,23199476.0,
303,724166,2,5,,103172342,3152,Active,14916950.0,540446.0,0.0042,IC50,Inhibition of bovine acetylcholinesterase using acetylcholine iodide as substrate incubated for 20 mins prior to substrate addition measured after 3 mins by Ellman's method,Confirmatory,23199476.0,
304,724167,5,2,,103172342,3152,Active,116353.0,590.0,2.0,IC50,Inhibition of butyrylcholinesterase (unknown origin),Confirmatory,23199476.0,
305,724168,5,2,,103172342,3152,Active,113037.0,43.0,0.002,IC50,Inhibition of acetylcholinesterase (unknown origin),Confirmatory,23199476.0,
306,725909,2,5,,103172342,3152,Active,584716.0,83817.0,0.032,IC50,Inhibition of AChE in Sprague-Dawley rat cortices using acetylthiocholine iodide as substrate by Ellman's method,Confirmatory,23273608.0,
307,725910,1,3,,103172342,3152,Active,,,43.0,IC50,Inhibition of BuChE in Sprague-Dawley rat serum by Ellman's method,Confirmatory,23273608.0,
308,725912,1,3,,103172342,3152,Unspecified,,,,,Selectivity ratio of IC50 for BuChE in Sprague-Dawley rat serum to IC50 for AChE in Sprague-Dawley rat cortices,Other,23273608.0,
309,725915,4,2,,103172342,3152,Active,113037.0,43.0,0.0057,IC50,Inhibition of AChE (unknown origin),Confirmatory,23273608.0,
310,745544,2,3,,103172342,3152,Active,113037.0,43.0,0.021,IC50,Inhibition of acetylcholine esterase (unknown origin) using acetylthiocholine as substrate incubated for 15 mins prior to substrate addition measured after 5 mins by spectrophotometry,Confirmatory,23603045.0,
311,748746,1,1,,103172342,3152,Unspecified,,,,,"Antiamnesic activity in Charles Foster albino rat assessed as reduction in scopolamine-induced increase in transfer latency at 10 mg/kg, po administered for 8 days measured 30 mins post last dose by elevated plus maze task (Rvb = 62.50 +/- 0.76 s)",Other,23562059.0,
312,748747,1,1,,103172342,3152,Unspecified,,,,,"Antiamnesic activity in Charles Foster albino rat assessed as reduction in scopolamine-induced increase in transfer latency at 5 mg/kg, po administered for 8 days measured 30 mins post last dose by elevated plus maze task (Rvb = 62.50 +/- 0.76 s)",Other,23562059.0,
313,748748,1,1,,103172342,3152,Unspecified,,,,,"Antiamnesic activity in Charles Foster albino rat assessed as reduction in scopolamine-induced increase in transfer latency at 10 mg/kg, po administered for 7 days measured 30 mins post last dose by elevated plus maze task (Rvb = 67.67 +/- 0.88 s)",Other,23562059.0,
314,748749,1,1,,103172342,3152,Unspecified,,,,,"Antiamnesic activity in Charles Foster albino rat assessed as reduction in scopolamine-induced increase in transfer latency at 5 mg/kg, po administered for 7 days measured 30 mins post last dose by elevated plus maze task (Rvb = 67.67 +/- 0.88 s)",Other,23562059.0,
315,748769,1,1,,103172342,3152,Unspecified,,,,,Selectivity ratio of IC50 for human serum BChE to IC50 for electric eel AChE,Other,23562059.0,
316,748770,2,3,,103172342,3152,Active,116353.0,590.0,15.24,IC50,Inhibition of human serum BChE using butyrylthiolcholine iodide as substrate incubated for 20 mins prior to substrate addition by Ellman's method,Confirmatory,23562059.0,
317,748771,2,3,,103172342,3152,Active,14916521.0,,0.04,IC50,Inhibition of electric eel AChE using acetylcholine iodide as substrate incubated for 20 mins prior to substrate addition by Ellman method,Confirmatory,23562059.0,
318,752341,3,2,,103172342,3152,Active,74752153.0,10280.0,0.0146,Ki,Displacement of [3H]DTG from sigma 1 receptor (unknown origin),Confirmatory,23582449.0,
319,759421,3,2,,103172342,3152,Active,116353.0,590.0,13.6,IC50,Inhibition of human BuChE using S-butyrylthiocholine iodide as substrate treated 5 mins before substrate addition measured up to 4 mins by Ellman's method,Confirmatory,23791077.0,
320,759422,2,3,,103172342,3152,Active,113037.0,43.0,0.04,IC50,Inhibition of human AChE using acetylthiocholine iodide as substrate treated 5 mins before substrate addition measured up to 4 mins by Ellman's method,Confirmatory,23791077.0,
321,763828,1,1,,103172342,3152,Unspecified,,,,,Cognitive enhancing effect in po dosed Wistar rat assessed as reversal of learning impairment measured as transfer latency administered for 8 days by elevated plus maze test,Other,23810675.0,
322,763829,1,1,,103172342,3152,Unspecified,,,,,"Cognitive enhancing effect in Wistar rat assessed as reversal of learning impairment measured as transfer latency at 10 mg/kg, po for 8 days measured on second day of test by elevated plus maze test (Rvb = 66.824 +/- 0.47 seconds)",Other,23810675.0,
323,763830,1,1,,103172342,3152,Unspecified,,,,,"Cognitive enhancing effect in Wistar rat assessed as reversal of learning impairment measured as transfer latency at 5 mg/kg, po for 8 days measured on second day of test by elevated plus maze test (Rvb = 66.824 +/- 0.47 seconds)",Other,23810675.0,
324,763831,1,1,,103172342,3152,Unspecified,,,,,"Cognitive enhancing effect in Wistar rat assessed as reversal of learning impairment measured as transfer latency at 10 mg/kg, po for 8 days measured on first day of test by elevated plus maze test (Rvb = 70.846 +/- 0.76 seconds)",Other,23810675.0,
325,763832,1,1,,103172342,3152,Unspecified,,,,,"Cognitive enhancing effect in Wistar rat assessed as reversal of learning impairment measured as transfer latency at 5 mg/kg, po for 8 days measured on first day of test by elevated plus maze test (Rvb = 70.846 +/- 0.76 seconds)",Other,23810675.0,
326,763833,1,2,,103172342,3152,Unspecified,,,,,"Activity at AChE in Charles Foster rat hypothalamus assessed as substrate hydrolyzed per mg of protein at 10 mg/kg, po for 8 days by Ellman's method (Rvb = 40.50 +/- 0.76 mol/min)",Other,23810675.0,
327,763834,1,2,,103172342,3152,Unspecified,,,,,"Activity at AChE in Charles Foster rat hypothalamus assessed as substrate hydrolyzed per mg of protein at 5 mg/kg, po for 8 days by Ellman's method (Rvb = 40.50 +/- 0.76 mol/min)",Other,23810675.0,
328,763835,1,2,,103172342,3152,Unspecified,,,,,"Activity at AChE in Charles Foster rat hippocampus assessed as substrate hydrolyzed per mg of protein at 10 mg/kg, po for 8 days by Ellman's method (Rvb = 47.50 +/- 0.84 mol/min)",Other,23810675.0,
329,763836,1,2,,103172342,3152,Unspecified,,,,,"Activity at AChE in Charles Foster rat hippocampus assessed as substrate hydrolyzed per mg of protein at 5 mg/kg, po for 8 days by Ellman's method (Rvb = 47.50 +/- 0.84 mol/min)",Other,23810675.0,
330,763837,1,2,,103172342,3152,Unspecified,,,,,"Activity at AChE in Charles Foster rat prefrontal cortex assessed as substrate hydrolyzed per mg of protein at 10 mg/kg, po for 8 days by Ellman's method (Rvb = 45.83 +/- 0.94 mol/min)",Other,23810675.0,
331,763838,1,2,,103172342,3152,Unspecified,,,,,"Activity at AChE in Charles Foster rat prefrontal cortex assessed as substrate hydrolyzed per mg of protein at 5 mg/kg, po for 8 days by Ellman's method (Rvb = 45.83 +/- 0.94 mol/min)",Other,23810675.0,
332,763839,1,1,,103172342,3152,Unspecified,,,,,"Cognitive enhancing effect in Charles Foster rat assessed as reversal of scopolamine-induced amnesia measured as transfer latency at 10 mg/kg, po for 8 days administered 1 hr prior to scopolamine-challenge on day 7 measured on day 8 by elevated plus maze test (Rvb = 62.17 +/- 0.47 seconds)",Other,23810675.0,
333,763840,1,1,,103172342,3152,Unspecified,,,,,"Cognitive enhancing effect in Charles Foster rat assessed as reversal of scopolamine-induced amnesia measured as transfer latency at 5 mg/kg, po for 8 days administered 1 hr prior to scopolamine-challenge on day 7 measured on day 8 by elevated plus maze test (Rvb = 62.17 +/- 0.47 seconds)",Other,23810675.0,
334,763841,1,1,,103172342,3152,Unspecified,,,,,"Cognitive enhancing effect in Charles Foster rat assessed as reversal of scopolamine-induced amnesia measured as transfer latency at 10 mg/kg, po for 8 days administered 1 hr prior to scopolamine-challenge on day 7 measured on same day by elevated plus maze test (Rvb = 67.83 +/- 0.94 seconds)",Other,23810675.0,
335,763842,1,1,,103172342,3152,Unspecified,,,,,"Cognitive enhancing effect in Charles Foster rat assessed as reversal of scopolamine-induced amnesia measured as transfer latency at 5 mg/kg, po for 8 days administered 1 hr prior to scopolamine-challenge on day 7 measured on same day by elevated plus maze test (Rvb = 67.83 +/- 0.94 seconds)",Other,23810675.0,
336,763843,2,3,,103172342,3152,Active,116353.0,590.0,12.54,Ki,Non competitive inhibition of human serum BChE using butyrylthiocholine iodide as substrate by Lineweaver-Burk plot analysis,Confirmatory,23810675.0,
337,763845,2,3,,103172342,3152,Active,14916521.0,,0.055999999999999994,Ki,Non competitive inhibition of electric eel AChE using acetylthiocholine iodide as substrate by Lineweaver-Burk plot analysis,Confirmatory,23810675.0,
338,763847,1,1,,103172342,3152,Unspecified,,,,,Selectivity ratio of IC50 for human serum BChE to IC50 for electric eel AChE,Other,23810675.0,
339,763848,2,3,,103172342,3152,Active,116353.0,590.0,15.24,IC50,Inhibition of human serum BChE using butyrylthiocholine iodide as substrate preincubated for 20 mins prior to substrate addition by Ellman's method,Confirmatory,23810675.0,
340,763849,4,2,,103172342,3152,Active,14916521.0,,0.04074,IC50,Inhibition of electric eel AChE using acetylthiocholine iodide as substrate preincubated for 20 mins prior to substrate addition by Ellman's method,Confirmatory,23810675.0,
341,768523,1,1,,103172342,3152,Unspecified,,,,,"Selectivity index, ratio of IC50 for human plasma BuChE to IC50 for purified human erythrocyte AChE",Other,23838422.0,
342,768524,2,3,,103172342,3152,Active,116353.0,590.0,2.5,IC50,Inhibition of human plasma BuChE using butyrylthiocholine as substrate by Ellman's method,Confirmatory,23838422.0,
343,768525,2,3,,103172342,3152,Active,113037.0,43.0,0.01,IC50,Inhibition of purified human erythrocyte AChE using acetylcholine as substrate by Ellman's method,Confirmatory,23838422.0,
344,771354,1,1,,103172342,3152,Unspecified,,,,,Selectivity ratio of IC50 for equine serum BChE to IC50 for electric eel AChE,Other,23988409.0,
345,771355,2,3,,103172342,3152,Active,21362409.0,100033901.0,5.38,IC50,Inhibition of equine serum BChE using butyrylthiocholine iodide as substrate after 2 mins by Ellman's method,Confirmatory,23988409.0,
346,771356,2,3,,103172342,3152,Active,14916521.0,,0.013999999999999999,IC50,Inhibition of electric eel AChE using acetylthiocholine iodide as substrate after 2 mins by Ellman's method,Confirmatory,23988409.0,
347,781329,1,2,,103172342,3152,Unspecified,,,,,pKa (acid-base dissociation constant) as determined by other workers,Other,24249037.0,
348,781330,1,2,,103172342,3152,Unspecified,,,,,pKa (acid-base dissociation constant) as determined by potentiometric titration,Other,24249037.0,
349,1055209,1,1,,103172342,3152,Unspecified,,,,,Activity at rat liver TrxR at 15 uM measured for 10 mins in presence of NADPH relative to control,Other,24160297.0,
350,1055210,1,2,,103172342,3152,Unspecified,,,,,Antioxidant activity assessed as peroxynitrite scavenging activity by Evans blue dye-based spectrophotometric analysis relative to control,Other,24160297.0,
351,1055211,1,2,,103172342,3152,Inactive,,,,,Antioxidant activity assessed as hydrogen peroxide scavenging activity after 10 hrs by FOX assay,Other,24160297.0,
352,1055212,1,1,,103172342,3152,Unspecified,,,,,Glutathione peroxidase-like activity of the compound in potassium phosphate buffer assessed as GSH-mediated reduction of H2O2 measured for 10 secs by spectrophotometric analysis (Rvb = 49.5 +/- 2.6 uM/min),Other,24160297.0,
353,1055213,1,4,,103172342,3152,Unspecified,113037.0,43.0,,,Inhibition of human recombinant AChE-induced amyloid beta (1 to 40) aggregation at 100 uM after 48 hrs by thioflavin T fluorescence assay relative to control,Other,24160297.0,
354,1055216,3,2,,103172342,3152,Active,113037.0,43.0,0.011000000000000001,IC50,Inhibition of human erythrocyte AChE using acetylthiocholine chloride as substrate preincubated for 15 mins followed by substrate addition measured every 1 min by Ellman's method,Confirmatory,24160297.0,
355,1055217,1,1,,103172342,3152,Unspecified,,,,,Selectivity ratio of IC50 for equine serum BuChE to IC50 for electric eel AChE,Other,24160297.0,
356,1055218,3,2,,103172342,3152,Active,21362409.0,100033901.0,3.365,IC50,Inhibition of equine serum BuChE using butyrylthiocholine chloride as substrate preincubated for 15 mins followed by substrate addition measured every 1 min by Ellman's method,Confirmatory,24160297.0,
357,1055219,3,2,,103172342,3152,Active,14916521.0,,0.038,IC50,Inhibition of electric eel AChE using acetylthiocholine chloride as substrate preincubated for 15 mins followed by substrate addition measured every 1 min by Ellman's method,Confirmatory,24160297.0,
358,1055866,1,1,,103172342,3152,Unspecified,,,,,"Selectivity index, ratio of IC50 for equine serum BChE to IC50 for electric eel AChE",Other,24211638.0,
359,1055867,2,3,,103172342,3152,Active,21362409.0,100033901.0,5.38,IC50,Inhibition of equine serum BChE using butyrylthiocholine iodide as substrate preincubated for 15 mins prior to substrate addition by Ellman's method,Confirmatory,24211638.0,
360,1055868,2,3,,103172342,3152,Active,14916521.0,,0.013999999999999999,IC50,Inhibition of electric eel AChE using acetylcholine as substrate preincubated for 15 mins prior to substrate addition by Ellman's method,Confirmatory,24211638.0,
361,1057006,1,4,,103172342,3152,Unspecified,113037.0,43.0,,,Mixed-type inhibition of human recombinant AChE-induced beta-amyloid (1 to 40) aggregation at 100 uM after 48 hrs by thioflavin T fluorescence spectroscopic analysis relative to control,Other,24128814.0,
362,1068375,2,3,,103172342,3152,Active,21362409.0,100033901.0,2.5,IC50,Inhibition of horse serum BuChE using butyrylthiocholine as substrate by Ellman's method,Confirmatory,24378710.0,
363,1068377,4,2,,103172342,3152,Active,113037.0,43.0,0.01,IC50,Inhibition of human AChE using acetylthiocholine as substrate by Ellman's method,Confirmatory,24378710.0,
364,1070081,1,1,,103172342,3152,Unspecified,,,,,GPx-like activity of the compound assessed as GSH-mediated H2O2 reduction at 80 uM at pH 7.5 measured for 10 secs by spectrophotometric analysis (Rvb = 39.46 +/- 1.5 uM/min),Other,24461494.0,
365,1070082,3,2,,103172342,3152,Active,113037.0,43.0,0.011000000000000001,IC50,Inhibition of human erythrocyte acetylcholinesterase using acetylthiocholine chloride as substrate preincubated for 15 mins followed by substrate addition by Ellman's method,Confirmatory,24461494.0,
366,1070083,3,2,,103172342,3152,Active,21362409.0,100033901.0,3.49,IC50,Inhibition of equine serum butyrylcholinesterase using butyrylthiocholine chloride as substrate preincubated for 15 mins followed by substrate addition by Ellman's method,Confirmatory,24461494.0,
367,1070084,3,2,,103172342,3152,Active,14916521.0,,0.040999999999999995,IC50,Inhibition of electric eel acetylcholinesterase using acetylthiocholine chloride as substrate preincubated for 15 mins followed by substrate addition by Ellman's method,Confirmatory,24461494.0,
368,1076172,4,2,,103172342,3152,Active,113980.0,4129.0,15.0,IC50,Inhibition of human recombinant MAO-B using tyramine as substrate preincubated for 30 mins followed by substrate addition measured for 1 hr by fluorometric assay,Confirmatory,24530494.0,
369,1076173,4,2,,103172342,3152,Unspecified,113978.0,4128.0,850.0,IC50,Inhibition of human recombinant MAO-A using tyramine as substrate preincubated for 30 mins followed by substrate addition measured for 1 hr by fluorometric assay,Confirmatory,24530494.0,
370,1076174,1,1,,103172342,3152,Unspecified,,,,,Selectivity ratio of IC50 for equine serum BuChE to IC50 for electric eel AChE,Other,24530494.0,
371,1076175,4,2,,103172342,3152,Active,21362409.0,100033901.0,0.84,IC50,Inhibition of equine serum BuChE using butyrylthiocholine iodide as substrate preincubated for 20 mins followed by substrate addition measured after 25 mins by Ellman's method,Confirmatory,24530494.0,
372,1076176,4,2,,103172342,3152,Active,14916521.0,,0.013000000000000001,IC50,Inhibition of electric eel AChE using acetylthiocholine iodide as substrate preincubated for 20 mins followed by substrate addition measured after 5 mins by Ellman's method,Confirmatory,24530494.0,
373,1076177,1,1,,103172342,3152,Unspecified,,,,,Selectivity ratio of IC50 for human recombinant MAO-B to IC50 for human recombinant MAO-A,Other,24530494.0,
374,1076764,1,1,,103172342,3152,Unspecified,,,,,Neuroprotective activity in Sprague-Dawley rat primary cortical neurons assessed as inhibition of glutamate-induced toxicity by measuring cell viability at 100 uM pretreated for 24 hrs followed by glutamate challenge measured after 24 hrs by MTT assay relative to control,Other,24581918.0,
375,1076765,1,1,,103172342,3152,Unspecified,,,,,Neuroprotective activity in Sprague-Dawley rat primary cortical neurons assessed as inhibition of glutamate-induced toxicity by measuring cell viability at 10 uM pretreated for 24 hrs followed by glutamate challenge measured after 24 hrs by MTT assay relative to control,Other,24581918.0,
376,1076766,1,1,,103172342,3152,Unspecified,,,,,Neuroprotective activity in Sprague-Dawley rat primary cortical neurons assessed as inhibition of glutamate-induced toxicity by measuring cell viability at 1 uM pretreated for 24 hrs followed by glutamate challenge measured after 24 hrs by MTT assay relative to control,Other,24581918.0,
377,1076767,1,1,,103172342,3152,Unspecified,,,,,Neuroprotective activity in Sprague-Dawley rat primary cortical neurons assessed as inhibition of glutamate-induced toxicity by measuring cell viability at 100 nM pretreated for 24 hrs followed by glutamate challenge measured after 24 hrs by MTT assay relative to control,Other,24581918.0,
378,1076768,1,1,,103172342,3152,Unspecified,,,,,Neuroprotective activity in Sprague-Dawley rat primary cortical neurons assessed as inhibition of glutamate-induced toxicity by measuring cell viability at 10 nM pretreated for 24 hrs followed by glutamate challenge measured after 24 hrs by MTT assay relative to control,Other,24581918.0,
379,1076769,1,1,,103172342,3152,Unspecified,,,,,Neuroprotective activity in Sprague-Dawley rat primary cortical neurons assessed as inhibition of amyloid beta 1 to 42-induced toxicity by measuring cell viability at 10 uM pretreated for 24 hrs followed by amyloid beta 1 to 42 challenge measured after 24 hrs by MTT assay relative to control,Other,24581918.0,
380,1076770,1,1,,103172342,3152,Unspecified,,,,,Neuroprotective activity in Sprague-Dawley rat primary cortical neurons assessed as inhibition of amyloid beta 1 to 42-induced toxicity by measuring cell viability at 1 uM pretreated for 24 hrs followed by amyloid beta 1 to 42 challenge measured after 24 hrs by MTT assay relative to control,Other,24581918.0,
381,1076771,1,1,,103172342,3152,Unspecified,,,,,Neuroprotective activity in Sprague-Dawley rat primary cortical neurons assessed as inhibition of amyloid beta 1 to 42-induced toxicity by measuring cell viability at 100 nM pretreated for 24 hrs followed by amyloid beta 1 to 42 challenge measured after 24 hrs by MTT assay relative to control,Other,24581918.0,
382,1076772,1,1,,103172342,3152,Unspecified,,,,,Neuroprotective activity in Sprague-Dawley rat primary cortical neurons assessed as inhibition of amyloid beta 1 to 42-induced toxicity by measuring cell viability at 10 nM pretreated for 24 hrs followed by amyloid beta 1 to 42 challenge measured after 24 hrs by MTT assay relative to control,Other,24581918.0,
383,1076775,1,1,,103172342,3152,Unspecified,,,,,Neuroprotective activity in Sprague-Dawley rat primary cortical neurons assessed as inhibition of amyloid beta 1 to 42-induced toxicity by measuring cell viability at 100 uM pretreated for 24 hrs followed by amyloid beta 1 to 42 challenge measured after 24 hrs by MTT assay relative to control,Other,24581918.0,
384,1077075,1,1,,103172342,3152,Active,,,,,"Cognition enhancing effect against scopolamine-induced memory deficit in Kunming mouse assessed as increase in latency time at 5 mg/kg, po administered 1 hr before training followed by scopolamine challenge for 7 days measured after 24 hrs by step-down passive avoidance test",Other,24589487.0,
385,1077080,1,4,,103172342,3152,Unspecified,113037.0,43.0,,,Inhibition of human erythrocytes AChE-induced amyloid beta (1 to 40) aggregation at 100 uM by thioflavin T fluorescence method,Other,24589487.0,
386,1077081,1,2,,103172342,3152,Unspecified,112927.0,351.0,,,Inhibition of Cu2+-induced amyloid beta (1 to 42) (unknown origin) aggregation at 25 uM after 24 hrs by thioflavin T fluorescence method,Other,24589487.0,
387,1077082,1,2,,103172342,3152,Unspecified,112927.0,351.0,,,Inhibition of self-induced amyloid beta (1 to 42) (unknown origin) aggregation at 25 uM after 24 hrs by thioflavin T fluorescence method,Other,24589487.0,
388,1077084,3,2,,103172342,3152,Active,81917534.0,,20.7,IC50,Inhibition of rat serum BuChE using butyrylthiocholine iodide as substrate after 15 mins by Ellman's method,Confirmatory,24589487.0,
389,1077085,1,3,,103172342,3152,Inconclusive,,,,,Antioxidant activity assessed as trolox equivalent of APPH-induced radical scavenging activity at 1 to 10 uM preincubated for 15 mins followed by AAPH challenge measured every minute for 90 minutes by ORAC fluorescence assay,Other,24589487.0,
390,1077088,2,3,,103172342,3152,Active,113037.0,43.0,0.011000000000000001,IC50,Inhibition of human erythrocytes AchE using acetylthiocholine iodide as substrate after 15 mins by Ellman's method,Confirmatory,24589487.0,
391,1077090,2,3,,103172342,3152,Active,14916521.0,,0.12,IC50,Inhibition of electric eel AchE using acetylthiocholine iodide as substrate after 15 mins by Ellman's method,Confirmatory,24589487.0,
392,1077092,2,3,,103172342,3152,Active,584716.0,83817.0,0.015,IC50,Inhibition of rat cortex homogenate AchE using acetylthiocholine iodide as substrate after 15 mins by Ellman's method,Confirmatory,24589487.0,
393,1077455,1,4,,103172342,3152,Unspecified,113037.0,43.0,,,Inhibition of human recombinant AChE assessed as reduction in Abeta fibrillogenesis at 100 uM by thioflavin T fluorescence spectroscopy,Other,,
394,1077458,1,4,,103172342,3152,Unspecified,14916521.0,,,,Displacement of propidium iodide from electric eel AChE peripheral anionic site at 10 uM by fluorescence assay,Other,,
395,1077460,2,2,,103172342,3152,Inconclusive,,,,IC50,Inhibition of horse serum BuChE using butyrylthiocholine chloride by spectrophotometry,Confirmatory,,
396,1077462,2,3,,103172342,3152,Active,113037.0,43.0,0.011000000000000001,IC50,Inhibition of human erythrocyte AChE using acetylthiocholine chloride by spectrophotometry,Confirmatory,,
397,1077464,2,3,,103172342,3152,Active,14916521.0,,0.02,IC50,Inhibition of electric eel AChE using acetylthiocholine chloride by spectrophotometry,Confirmatory,,
398,1079931,1,1,,103172342,3152,Unspecified,,,,,"Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]",Other,15646539.0,
399,1079932,1,1,,103172342,3152,Unspecified,,,,,"Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]",Other,15646539.0,
400,1079933,1,1,,103172342,3152,Unspecified,,,,,"Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is number of references indexed. [column 'AIGUE' in source]",Other,15646539.0,
401,1079934,1,1,,103172342,3152,Unspecified,,,,,"Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]",Other,15646539.0,
402,1079935,1,1,,103172342,3152,Unspecified,,,,,"Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]",Other,15646539.0,
403,1079936,1,1,,103172342,3152,Unspecified,,,,,"Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]",Other,15646539.0,
404,1079937,1,1,,103172342,3152,Unspecified,,,,,"Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]",Other,15646539.0,
405,1079938,1,1,,103172342,3152,Unspecified,,,,,"Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]",Other,15646539.0,
406,1079939,1,1,,103172342,3152,Unspecified,,,,,"Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]",Other,15646539.0,
407,1079940,1,1,,103172342,3152,Unspecified,,,,,"Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]",Other,15646539.0,
408,1079941,1,1,,103172342,3152,Unspecified,,,,,"Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]",Other,15646539.0,
409,1079942,1,1,,103172342,3152,Unspecified,,,,,"Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]",Other,15646539.0,
410,1079943,1,1,,103172342,3152,Unspecified,,,,,"Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]",Other,15646539.0,
411,1079944,1,1,,103172342,3152,Unspecified,,,,,"Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]",Other,15646539.0,
412,1079945,1,1,,103172342,3152,Unspecified,,,,,Animal toxicity known. [column 'TOXIC' in source],Other,15646539.0,
413,1079946,1,1,,103172342,3152,Unspecified,,,,,Presence of at least one case with successful reintroduction. [column 'REINT' in source],Other,15646539.0,
414,1079947,1,1,,103172342,3152,Unspecified,,,,,Comments (NB not yet translated). [column 'COMMENTAIRES' in source],Other,15646539.0,
415,1079948,1,1,,103172342,3152,Unspecified,,,,,"Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]",Other,15646539.0,
416,1079949,1,1,,103172342,3152,Unspecified,,,,,Proposed mechanism(s) of liver damage. [column 'MEC' in source],Other,15646539.0,
417,1113329,1,2,,103172342,3152,Active,,,,,"Antiamnestic activity in scopolamine-induced Swiss albino Mus musculus (mouse) memory deficit model assessed as increase in time spent in target quadrant at 25 mg/kg, ip administered 30 min prior to scopolamine challenge measured on day 5 by Morris water maze test relative to vehicle-treated control",Other,,
418,1113331,1,2,,103172342,3152,Unspecified,,,,,"Antiamnestic activity in scopolamine-induced Swiss albino Mus musculus (mouse) memory deficit model assessed as escape latency time at 25 mg/kg, ip administered 30 min prior to scopolamine challenge measured on day 4 by Morris water maze test (Rvb = 78.7 +/- 5.7 secs)",Other,,
419,1113335,1,2,,103172342,3152,Unspecified,,,,,"Antiamnestic activity in scopolamine-induced Swiss albino Mus musculus (mouse) memory deficit model assessed as escape latency time at 25 mg/kg, ip administered 30 min prior to scopolamine challenge measured on day 1 by Morris water maze test (Rvb = 89.7 +/- 3.8 secs)",Other,,
420,1113337,2,3,,103172342,3152,Active,584716.0,83817.0,0.0215,IC50,Inhibition of AchE in Rattus norvegicus (rat) cortex homogenates by Ellman's method,Confirmatory,,
421,1113849,4,2,,103172342,3152,Active,584716.0,83817.0,0.01585,IC50,Inhibition of acetylcholinesterase in Rattus norvegicus (rat) cortex by Ellman method,Confirmatory,,
422,1120193,1,3,,103172342,3152,Unspecified,14916521.0,,,,Inhibition of electric eel AChE using acetylthiocholine iodide as substrate at 10'-5 M preincubated for 5 mins before substrate addition measured for 10 mins by Ellman's method,Other,,
423,1120194,1,3,,103172342,3152,Unspecified,14916521.0,,,,Displacement of propidium iodide from electric eel AChE at 10'-5 M after 15 mins by fluorescence assay,Other,,
424,1120195,3,2,,103172342,3152,Active,14916521.0,,0.0203,IC50,Inhibition of electric eel AChE using acetylthiocholine iodide as substrate preincubated for 5 mins before substrate addition measured for 10 mins by Ellman's method,Confirmatory,,
425,1120233,1,3,,103172342,3152,Active,14916521.0,,0.09,IC50,Inhibition of Electrophorus electricus AChE using acetylthiocholine iodide as substrate after 30 mins by Ellman's method,Confirmatory,,
426,1120234,1,3,,103172342,3152,Active,21362409.0,100033901.0,5.52,IC50,Inhibition of equine serum BuChE using S-butyrylthiocholine iodide as substrate after 30 mins by Ellman's method,Confirmatory,,
427,1120235,1,1,,103172342,3152,Unspecified,,,,,Selectivity ratio of IC50 for equine serum BuChE to IC50 for Electrophorus electricus AChE,Other,,
428,1125766,2,2,,103172342,3152,Active,14916521.0,,0.033,IC50,Inhibition of electric eel AChE using acetylthiocholine iodide as substrate preincubated with enzyme for 10 mins prior to substrate challenge measured after 15 mins by Ellman's method,Confirmatory,24657052.0,
429,1125767,2,2,,103172342,3152,Active,21362409.0,100033901.0,1.82,IC50,Inhibition of BuChE in equine serum using butyrylthiocholine iodide as substrate preincubated with enzyme for 10 mins prior to substrate challenge measured after 15 mins by Ellman's method,Confirmatory,24657052.0,
430,1125768,1,1,,103172342,3152,Unspecified,,,,,Selectivity ratio of IC50 for BuChE in equine serum to IC50 for electric eel AChE,Other,24657052.0,
431,1126181,1,3,,103172342,3152,Active,14916521.0,,0.03,IC50,Inhibition of electric eel acetylcholinesterase using acetylthiocholine iodide as substrate preincubated for 10 mins before substrate addition after 15 mins by Ellman's method,Confirmatory,24675179.0,
432,1126182,1,3,,103172342,3152,Active,116353.0,590.0,6.37,IC50,Inhibition of human BChE using butyrylthiocholine iodide as substrate preincubated for 10 mins before substrate addition after 15 mins by Ellman's method,Confirmatory,24675179.0,
433,1126626,1,3,,103172342,3152,Active,14916521.0,,0.03,IC50,Inhibition of electric eel acetylcholinesterase using acetylthiocholine iodide as substrate preincubated for 10 mins before substrate addition after 15 mins by Ellman's method,Confirmatory,24681981.0,
434,1126627,1,3,,103172342,3152,Active,116353.0,590.0,6.37,IC50,Inhibition of human BChE using butyrylthiocholine iodide as substrate preincubated for 10 mins before substrate addition after 15 mins by Ellman's method,Confirmatory,24681981.0,
435,1152907,2,2,,103172342,3152,Active,14916521.0,,0.0067,IC50,Inhibition of electric eel AChE using acetylthiocholine iodide as substrate preincubated for 20 mins followed by substrate addition measured after 5 mins by Ellman's method,Confirmatory,24813882.0,
436,1152908,2,2,,103172342,3152,Active,21362409.0,100033901.0,7.4,IC50,Inhibition of equine serum BuChE using butyrylthiocholine iodide as substrate preincubated for 20 mins followed by substrate addition measured after 25 mins by Ellman's method,Confirmatory,24813882.0,
437,1152909,1,1,,103172342,3152,Unspecified,,,,,"Selectivity index, ratio of IC50 for equine serum BuChE to IC50 for electric eel AChE",Other,24813882.0,
438,1152914,1,3,,103172342,3152,Unspecified,113979.0,29253.0,850.0,IC50,Inhibition of MAO-A in rat liver homogenate using [14C]-5HT as substrate preincubated for 30 mins followed by substrate addition measured after 20 mins by liquid scintillation counting analysis,Confirmatory,24813882.0,
439,1152915,1,3,,103172342,3152,Active,124028639.0,25750.0,15.0,IC50,Inhibition of MAO-B in rat liver homogenate using [14C]-phenylethylamine as substrate preincubated for 30 mins followed by substrate addition measured after 4 mins by liquid scintillation counting analysis,Confirmatory,24813882.0,
440,1152916,1,2,,103172342,3152,Unspecified,,,,,"Selectivity index, ratio of IC50 for MAO-B in rat liver homogenate to IC50 for MAO-A in rat liver homogenate",Other,24813882.0,
441,1152932,1,1,,103172342,3152,Unspecified,,,,,Hepatotoxicity in human HepG2 cells assessed as cell viability at 1 uM by MTT assay relative to control,Other,24813882.0,
442,1152933,1,1,,103172342,3152,Unspecified,,,,,Hepatotoxicity in human HepG2 cells assessed as cell viability at 3 uM by MTT assay relative to control,Other,24813882.0,
443,1152934,1,1,,103172342,3152,Unspecified,,,,,Hepatotoxicity in human HepG2 cells assessed as cell viability at 10 uM by MTT assay relative to control,Other,24813882.0,
444,1152935,1,1,,103172342,3152,Unspecified,,,,,Hepatotoxicity in human HepG2 cells assessed as cell viability at 30 uM by MTT assay relative to control,Other,24813882.0,
445,1152936,1,1,,103172342,3152,Unspecified,,,,,Hepatotoxicity in human HepG2 cells assessed as cell viability at 100 uM by MTT assay relative to control,Other,24813882.0,
446,1152937,1,1,,103172342,3152,Unspecified,,,,,Hepatotoxicity in human HepG2 cells assessed as cell viability at 300 uM by MTT assay relative to control,Other,24813882.0,
447,1152938,1,1,,103172342,3152,Unspecified,,,,,Hepatotoxicity in human HepG2 cells assessed as cell viability at 1000 uM by MTT assay relative to control,Other,24813882.0,
448,1152940,1,1,,103172342,3152,Active,,,,,"Cognitive enhancing effect in C57BL/6J mouse assessed as reversal of scopolamine-induced long-term memory deficit by measuring increase in latency time during probe session at 1 mg/kg, iv administered 90 mins prior to scopolamine-challenge measured after 24 hrs by passive avoidance test",Other,24813882.0,
449,1152941,1,1,,103172342,3152,Unspecified,,,,,Effective permeability across human intestinal membrane by Ussing chamber technique,Other,24813882.0,
450,1152942,1,2,,103172342,3152,Unspecified,,,,,Drug absorption in human intestine,Other,24813882.0,
451,1152943,1,1,,103172342,3152,Unspecified,,,,,Permeability in human Caco2 cells,Other,24813882.0,
452,1152944,1,1,,103172342,3152,Unspecified,,,,,Apparent permeability in MDCK cells,Other,24813882.0,
453,1152945,1,2,,103172342,3152,Unspecified,,,,,Protein binding in plasma (unknown origin),Other,24813882.0,
454,1152947,1,1,,103172342,3152,Inactive,,,,,"Cognitive enhancing effect in C57BL/6J mouse assessed as reversal of scopolamine-induced long-term memory deficit by measuring latency time during training session at 1 mg/kg, iv administered 90 mins prior to scopolamine-challenge measured after 24 hrs by passive avoidance test",Other,24813882.0,
455,1156022,1,3,,103172342,3152,Active,14916521.0,,0.022000000000000002,IC50,Inhibition of electric eel AChE using acetylthiocholine iodide as substrate by spectrophotometer analysis,Confirmatory,24941128.0,
456,1156023,1,3,,103172342,3152,Active,21362409.0,100033901.0,7.3,IC50,Inhibition of equine serum BChE using butyrylthiocholine iodide as substrate by spectrophotometer analysis,Confirmatory,24941128.0,
457,1156822,2,2,,103172342,3152,Active,113037.0,43.0,0.062,IC50,Inhibition of AChE (unknown origin) after 5 mins by Ellman's method,Confirmatory,24980117.0,
458,1156823,2,2,,103172342,3152,Active,116353.0,590.0,6.92,IC50,Inhibition of BuChE (unknown origin) after 5 mins by Ellman's method,Confirmatory,24980117.0,
459,1156824,1,1,,103172342,3152,Unspecified,,,,,Selectivity ratio of IC50 for BuChE (unknown origin) to IC50 for AChE (unknown origin),Other,24980117.0,
460,1159387,1,2,,103172342,3152,Unspecified,,,,,"ASTRAZENECA: Octan-1-ol/water (pH7.4) distribution coefficent measured  by a shake flask method described in J. Biomol. Screen. 2011, 16, 348-355. Experimental range -1.5 to 4.5",Other,,
461,1159389,1,2,,103172342,3152,Unspecified,,,,,"ASTRAZENECA: % bound to plasma by equilibrium dialysis. Compound is incubated with whole human plasma  at 37C for >5hrs.  Method described in B. Testa et al (Eds.), Pharmacokinetic Profiling in Drug Research: Biological, Physicochemical, and Computational Strategies, Wiley-VCH, Weinheim, 2006, pp.119-141. Experimental range 10% to 99.95% bound.",Other,,
462,1159390,1,2,,103172342,3152,Unspecified,,,,,"ASTRAZENECA: % bound to plasma by equilibrium dialysis. Compound is incubated with whole rat plasma  at 37C for >5hrs.  Method described in B. Testa et al (Eds.), Pharmacokinetic Profiling in Drug Research: Biological, Physicochemical, and Computational Strategies, Wiley-VCH, Weinheim, 2006, pp.119-141. Experimental range 10% to 99.95% bound.",Other,,
463,1159391,1,2,,103172342,3152,Unspecified,,,,,"ASTRAZENECA: % bound to plasma by equilibrium dialysis. Compound is incubated with whole dog plasma  at 37C for >5hrs.  Method described in B. Testa et al (Eds.), Pharmacokinetic Profiling in Drug Research: Biological, Physicochemical, and Computational Strategies, Wiley-VCH, Weinheim, 2006, pp.119-141. Experimental range 10% to 99.95% bound.",Other,,
464,1159580,2,1,,268735039,3152,Inactive,,,,,"The chemical genetic matrix (CGM) dataset as reported in Wildenhain et al. (2015) Prediction of Synergism from Chemical-Genetic Interactions by Machine Learning. Cell Systems Volume 1, Issue 6, p383-395",Summary,,
465,1159607,2,1,,312310068,3152,Inactive,,,,,Screen for inhibitors of RMI FANCM (MM2) intereaction,Other,26962873.0,
466,1162589,1,2,,103172342,3152,Active,113037.0,43.0,0.008,IC50,Inhibition of human recombinant AChE using acetylthiocholine iodide substrate incubated for 15 mins by spectrophotometry based Ellman's method,Confirmatory,25189690.0,
467,1162590,1,2,,103172342,3152,Active,116353.0,590.0,7.1,IC50,Inhibition of human recombinant BuChE using butyrylthiocholine iodide substrate incubated for 15 mins by spectrophotometry based Ellman's method,Confirmatory,25189690.0,
468,1162591,1,1,,103172342,3152,Unspecified,,,,,"Selectivity index, ratio of IC50 for human recombinant BuChE to IC50 for human recombinant AChE",Other,25189690.0,
469,1162593,1,1,,103172342,3152,Unspecified,,,,,"Antagonism of scopolamine-induced passive avoidance in Wistar rat assessed as latency of visiting dark box measured for 5 mins at 1 mg/kg, po dosed 30 mins after scopolamine challenge and measured 1 hr post dose",Other,25189690.0,
470,1166296,1,2,,103172342,3152,Active,14916521.0,,7.23,IC50,Inhibition of electric eel AChE by Ellman's method,Confirmatory,25257911.0,
471,1166298,1,2,,103172342,3152,Active,116353.0,590.0,0.02,IC50,Inhibition of human BChE by Ellman's method,Confirmatory,25257911.0,
472,1167540,1,2,,103172342,3152,Active,14916521.0,,0.0382,IC50,Inhibition of electric eel AChE preincubated for 15 mins by Ellman's method,Confirmatory,25282266.0,
473,1167541,1,2,,103172342,3152,Active,75074633.0,,3.3654,IC50,Inhibition of equine BChE preincubated for 15 mins by Ellman's method,Confirmatory,25282266.0,
474,1167542,1,1,,103172342,3152,Unspecified,,,,,Selectivity ratio of IC50 for equine BChE to IC50 for electric eel AChE,Other,25282266.0,
475,1167543,1,2,,103172342,3152,Active,113037.0,43.0,0.0117,IC50,Inhibition of human erythrocyte AChE preincubated for 15 mins by Ellman's method,Confirmatory,25282266.0,
476,1167544,1,2,,103172342,3152,Active,113037.0,43.0,,,Mixed-type inhibition of human erythrocyte AChE by Lineweaver-Burk reciprocal plot method,Other,25282266.0,
477,1167545,1,1,,103172342,3152,Inconclusive,,,,,Antioxidant activity assessed as oxygen radical absorbance capacity preincubated for 10 mins by fluorescence assay relative to trolox,Other,25282266.0,
478,1176151,1,2,,103172342,3152,Unspecified,116241312.0,1576.0,,,Inhibition of human recombinant CYP3A4 expressed in insect cell microsomes preincubated for 10 mins at 0.1 uM by fluorescence assay,Other,25499431.0,
479,1176152,1,2,,103172342,3152,Unspecified,116241312.0,1576.0,,,Inhibition of human recombinant CYP3A4 expressed in insect cell microsomes preincubated for 10 mins at 1 uM by fluorescence assay,Other,25499431.0,
480,1176153,1,2,,103172342,3152,Unspecified,116241312.0,1576.0,,,Inhibition of human recombinant CYP3A4 expressed in insect cell microsomes preincubated for 10 mins at 10 uM by fluorescence assay,Other,25499431.0,
481,1176154,1,2,,103172342,3152,Unspecified,116241312.0,1576.0,,,Inhibition of human recombinant CYP3A4 expressed in insect cell microsomes preincubated for 10 mins at 100 uM by fluorescence assay,Other,25499431.0,
482,1176155,1,2,,103172342,3152,Unspecified,116241312.0,1576.0,,,Inhibition of human recombinant CYP3A4 expressed in insect cell microsomes preincubated for 10 mins at 250 uM by fluorescence assay,Other,25499431.0,
483,1176156,1,2,,103172342,3152,Unspecified,116241312.0,1576.0,,,Inhibition of human recombinant CYP3A4 expressed in insect cell microsomes preincubated for 10 mins at 500 uM by fluorescence assay,Other,25499431.0,
484,1176157,1,2,,103172342,3152,Unspecified,116241312.0,1576.0,54.68,IC50,Inhibition of human recombinant CYP3A4 expressed in insect cell microsomes preincubated for 10 mins by fluorescence assay,Confirmatory,25499431.0,
485,1176158,1,2,,103172342,3152,Unspecified,238054374.0,5243.0,,,Inhibition of human recombinant MDR1 in cell membrane fraction preincubated for 5 mins at 0.01 uM measured after 40 mins by Pgp-Glo luciferase assay,Other,25499431.0,
486,1176159,1,2,,103172342,3152,Unspecified,238054374.0,5243.0,,,Inhibition of human recombinant MDR1 in cell membrane fraction preincubated for 5 mins at 0.1 uM measured after 40 mins by Pgp-Glo luciferase assay,Other,25499431.0,
487,1176160,1,2,,103172342,3152,Unspecified,238054374.0,5243.0,,,Inhibition of human recombinant MDR1 in cell membrane fraction preincubated for 5 mins at 1 uM measured after 40 mins by Pgp-Glo luciferase assay,Other,25499431.0,
488,1176161,1,2,,103172342,3152,Unspecified,238054374.0,5243.0,,,Inhibition of human recombinant MDR1 in cell membrane fraction preincubated for 5 mins at 10 uM measured after 40 mins by Pgp-Glo luciferase assay,Other,25499431.0,
489,1176162,1,2,,103172342,3152,Unspecified,238054374.0,5243.0,,,Inhibition of human recombinant MDR1 in cell membrane fraction preincubated for 5 mins at 100 uM measured after 40 mins by Pgp-Glo luciferase assay,Other,25499431.0,
490,1176163,1,2,,103172342,3152,Active,238054374.0,5243.0,34.85,IC50,Inhibition of human recombinant MDR1 in cell membrane fraction preincubated for 5 mins measured after 40 mins by Pgp-Glo luciferase assay,Confirmatory,25499431.0,
491,1176164,1,2,,103172342,3152,Active,,,,,"Total steady state plasma concentration in Sprague-Dawley rat at 5 mg/kg, po",Other,25499431.0,
492,1176165,1,1,,103172342,3152,Unspecified,,,,,"Fraction unbound in Sprague-Dawley rat at 5 mg/kg, po",Other,25499431.0,
493,1176166,1,1,,103172342,3152,Unspecified,,,,,Absolute bioavailability in dog,Other,25499431.0,
494,1176167,1,1,,103172342,3152,Unspecified,,,,,Oral bioavailability in human,Other,25499431.0,
495,1184268,1,2,,103172342,3152,Active,14916521.0,,0.013999999999999999,IC50,Inhibition of electric eel AChE using acetylthiocholine iodide substrate by Ellman method based spectrophotometry,Confirmatory,25036795.0,
496,1184269,1,2,,103172342,3152,Active,21362409.0,100033901.0,5.38,IC50,Inhibition of equine serum BuChE using butyrylthiocholine iodide substrate by Ellman method based spectrophotometry,Confirmatory,25036795.0,
497,1184270,1,1,,103172342,3152,Unspecified,,,,,"Selectivity index, ratio of IC50 for equine serum BuChE to IC50 for electric eel AChE",Other,25036795.0,
498,1186312,1,2,,103172342,3152,Active,584716.0,83817.0,0.011000000000000001,IC50,Inhibition of AChE in rat cortex homogenates using acetylthiocholine iodide substrate incubated for 15 mins by UV spectroscopy based Ellman's method,Confirmatory,25082512.0,
499,1186313,1,2,,103172342,3152,Active,81917534.0,,1.28,IC50,Inhibition of BChE in rat serum using butyrylthiocholine iodide substrate incubated for 15 mins by UV spectroscopy based Ellman's method,Confirmatory,25082512.0,
500,1191627,1,2,,103172342,3152,Active,14916521.0,,0.048,IC50,Inhibition of electric eel AChE using acetylthiocholine iodide as substrate incubated for 5 mins by Ellman's method,Confirmatory,25624107.0,
501,1191628,1,2,,103172342,3152,Active,21362409.0,100033901.0,1.911,IC50,Inhibition of equine serum BChE using butyrylthiocholine iodide as substrate incubated for 5 mins by Ellman's method,Confirmatory,25624107.0,
502,1191629,1,1,,103172342,3152,Unspecified,,,,,Selectivity ratio of IC50 for equine serum BChE to IC50 for electric eel AChE,Other,25624107.0,
503,1191631,1,2,,103172342,3152,Inconclusive,,,,,Antioxidant activity assessed as trolox equivalent of AAPH radical scavenging activity at 1 to 10 uM preincubated for 15 mins followed by AAPH challenge measured every min for 80 mins by ORAC-FL assay,Other,25624107.0,
504,1191938,1,2,,103172342,3152,Active,584716.0,83817.0,0.015,IC50,Inhibition of AChE from rat cortex homogenate using acetylthiocholine iodide as substrate after 15 mins by Ellman method,Confirmatory,25678013.0,
505,1191939,1,2,,103172342,3152,Active,,,20.7,IC50,Inhibition of rat serum BuChE using butyrylthiocholine iodide as substrate after 15 mins by Ellman method,Confirmatory,25678013.0,
506,1191940,1,2,,103172342,3152,Active,14916521.0,,0.11,IC50,Inhibition of electric eel AChE using acetylthiocholine iodide as substrate after 15 mins by Ellman method,Confirmatory,25678013.0,
507,1191941,1,2,,103172342,3152,Unspecified,,,,,"Selectivity index, ratio of IC50 for rat serum BuChE to IC50 for AChE from rat cortex homogenate",Other,25678013.0,
508,1191948,1,2,,103172342,3152,Unspecified,112927.0,351.0,,,Inhibition of self-mediated aggregation of amyloid beta (1-42) (unknown origin) at 25 uM after 24 hrs by thioflavin T fluorescence-based fluorimetric method,Other,25678013.0,
509,1191949,1,2,,103172342,3152,Unspecified,112927.0,351.0,,,Inhibition of Cu2+-mediated aggregation of amyloid beta (1-42) (unknown origin) at 25 uM after 24 hrs by thioflavin T fluorescence-based fluorimetric method,Other,25678013.0,
510,1193152,1,2,,103172342,3152,Active,14916521.0,,0.01,IC50,Inhibition of Electrophorus electricus AChE pre-incubated for 5 mins before addition of acetylthiocholine iodide substrate by Ellman's assay,Confirmatory,25707322.0,
511,1193153,1,2,,103172342,3152,Active,21362409.0,100033901.0,1.83,IC50,Inhibition of BuChE in horse serum pre-incubated for 5 mins before addition of butyrylthiocholine iodide substrate by Ellman's assay,Confirmatory,25707322.0,
512,1193154,1,1,,103172342,3152,Unspecified,,,,,"Selectivity index, ratio of IC50 for BuChE in horse serum to IC50 for Electrophorus electricus AChE",Other,25707322.0,
513,1193155,1,2,,103172342,3152,Active,113037.0,43.0,0.006,IC50,Inhibition of human recombinant AChE pre-incubated for 5 mins before addition of acetylthiocholine iodide substrate by Ellman's assay,Confirmatory,25707322.0,
514,1195130,1,2,,103172342,3152,Active,14916521.0,,26.1,IC50,Inhibition of electric eel AChE using acetylthiocholine iodide as substrate preincubated for 5 mins by Ellman method,Confirmatory,25868744.0,
515,1195131,1,2,,103172342,3152,Active,21362409.0,100033901.0,4.46,IC50,Inhibition of horse serum BChE using butyrylthiocholine iodide as substrate preincubated for 5 mins by Ellman method,Confirmatory,25868744.0,
516,1195134,1,1,,103172342,3152,Unspecified,,,,,Inhibition of self-induced beta-amyloid (1 to 42) (unknown origin) at 10 uM aggregation by thioflavin-T assay,Other,25868744.0,
517,1195138,1,1,,103172342,3152,Active,,,,,"Effect on scopolamine-induced cognitive dysfunction in albino Swiss CD-1 mouse assessed as reduction in step-through latency time at 5 to 10 mg/kg, ip administered 1 hr before the acquisition trial by passive avoidance test",Other,25868744.0,
518,1195140,1,1,,103172342,3152,Active,,,,,"Effect on scopolamine-induced cognitive dysfunction in albino Swiss CD-1 mouse assessed as reduction in step-through latency time during retention trial at 5 to 10 mg/kg, ip administered 1 hr before the acquisition trial measured 24 hrs after acquisition trial over 180 seconds by passive avoidance test",Other,25868744.0,
519,1195740,1,2,,103172342,3152,Inconclusive,113978.0,4128.0,,IC50,Inhibition of human MAO-A expressed in baculovirus infected BTI insect cells preincubated for 15 mins,Confirmatory,25418133.0,
520,1195741,1,2,,103172342,3152,Inconclusive,113980.0,4129.0,,IC50,Inhibition of human MAO-B expressed in baculovirus infected BTI insect cells preincubated for 15 mins,Confirmatory,25418133.0,
521,1195742,1,2,,103172342,3152,Active,113037.0,43.0,0.016,IC50,Inhibition of recombinant human AChE expressed in HEK293 cells preincubated for 15 mins,Confirmatory,25418133.0,
522,1195743,1,2,,103172342,3152,Active,116353.0,590.0,8.2,IC50,Inhibition of recombinant human BuChE expressed in HEK293 cells preincubated for 15 mins,Confirmatory,25418133.0,
523,1199518,1,2,,103172342,3152,Active,14916521.0,,0.01,IC50,Inhibition of Electrophorus electricus AChE after 5 mins by Ellman's method,Confirmatory,25621991.0,
524,1199519,1,2,,103172342,3152,Active,21362409.0,100033901.0,1.83,IC50,Inhibition of equine serum BuChE after 5 mins by Ellman's method,Confirmatory,25621991.0,
525,1199520,1,1,,103172342,3152,Unspecified,,,,,"Selectivity index, ratio of IC50 for equine serum BuChE to IC50 for Electrophorus electricus AChE",Other,25621991.0,
526,1199521,1,2,,103172342,3152,Active,113037.0,43.0,0.006,IC50,Inhibition of human recombinant AChE after 5 mins by Ellman's method,Confirmatory,25621991.0,
527,1199524,1,2,,103172342,3152,Unspecified,112927.0,351.0,,,Inhibition of human recombinant amyloid beta (1 to 42) self-induced aggregation at 10 uM after 24 hrs by thioflavin-T based fluorometric assay,Other,25621991.0,
528,1201371,1,2,,103172342,3152,Active,14916521.0,,0.013999999999999999,IC50,Inhibition of electric eel AChE incubated for 15 mins using acetylcholine iodide substrate by colorimetric Ellman's method,Confirmatory,25768702.0,
529,1201372,1,2,,103172342,3152,Active,21362409.0,100033901.0,3.31,IC50,Inhibition of equine serum butyrylcholine esterase incubated for 15 mins using S-butyrylthiocholine chloride substrate by colorimetric Ellman's method,Confirmatory,25768702.0,
530,1201373,1,1,,103172342,3152,Unspecified,,,,,"Selectivity index, ratio of IC50 for equine serum butyrylcholine esterase to IC50 for electric eel AChE",Other,25768702.0,
531,1201374,1,1,,103172342,3152,Unspecified,,,,,In vitro blood-brain barrier permeability at pH 7.4 by UV detection and HPLC based PAMPA method,Other,25768702.0,
532,1201375,1,2,,103172342,3152,Unspecified,,,,,In vitro blood-brain barrier permeability by PAMPA method,Other,25768702.0,
533,1201378,1,2,,103172342,3152,Unspecified,,,,,Half life in Sprague-Dawley rat liver microsomes at 2 uM at pH 7.4 pre-incubated in presence of NADPH regenerating system measured 30 mins after microsomal reactions termination by LC-MS method,Other,25768702.0,
534,1201381,1,2,,103172342,3152,Unspecified,,,,,Stability in Sprague-Dawley rat liver microsomes assessed as parent compound remaining at 2 uM measured 30 mins after microsomal reactions termination at pH 7.4 pre-incubated in presence of NADPH regenerating system by LC-MS method,Other,25768702.0,
535,1201382,1,1,,103172342,3152,Unspecified,,,,,Retention time of the compound by HPLC-fluorescence method,Other,25768702.0,
536,1201546,1,2,,103172342,3152,Active,113037.0,43.0,0.006,IC50,Inhibition of human erythrocyte AChE pre-incubated for 5 mins before acetylthiocholine iodide substrate by Ellman' method,Confirmatory,25793650.0,
537,1201548,1,2,,103172342,3152,Active,21362409.0,100033901.0,7.0,IC50,Inhibition of equine serum BuChE pre-incubated for 5 mins before butyrylthiocholine iodide substrate by Ellman' method,Confirmatory,25793650.0,
538,1201554,1,2,,103172342,3152,Unspecified,14916521.0,,,,Inhibition of propidium iodide binding to peripheral anionic site of electric eel AChE at 10 uM incubated for 6 hrs by propidium competition assay,Other,25793650.0,
539,1201558,1,1,,103172342,3152,Active,,,,,"Antiamnesic activity in NMRI mouse assessed as reversal of scopolamine-induced spontaneous alteration deficit at 1 mg/kg, ip by Y maze test",Other,25793650.0,
540,1202691,1,2,,103172342,3152,Active,14916521.0,,0.00424,Ki,Inhibition of electric eel AChE pre-incubated for 3 mins before acetylthiocholine substrate addition by Lineweaver-Burk plot,Confirmatory,25969170.0,
541,1207739,1,1,,103172342,3152,Active,,,34.3,IC50,"Inhibition of Cav1.2 current measured using QPatch automatic path clamp system in CHO cells expressing Cav1.2, beta-2 and alpha-2/delta-1 subunits",Confirmatory,23812503.0,
542,1209455,1,2,,103172342,3152,Unspecified,262527527.0,8647.0,205.7,IC50,Inhibition of human BSEP expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake,Confirmatory,21965623.0,
543,1209456,1,2,,103172342,3152,Unspecified,12585136.0,83569.0,519.3,IC50,Inhibition of Sprague-Dawley rat Bsep expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake,Confirmatory,21965623.0,
544,1209457,1,1,,103172342,3152,Active,,,,,Unbound Cmax in human plasma,Other,21965623.0,
545,1217704,1,2,,103172342,3152,Unspecified,117144.0,1544.0,,,Time dependent inhibition of CYP1A2 (unknown origin) at 100 uM by LC/MS system,Other,21467212.0,
546,1217705,1,2,,103172342,3152,Unspecified,117205.0,1555.0,,,Time dependent inhibition of CYP2B6 (unknown origin) at 100 uM by LC/MS system,Other,21467212.0,
547,1217706,1,2,,103172342,3152,Unspecified,6686268.0,1559.0,,,Time dependent inhibition of CYP2C9 (unknown origin) at 100 uM by LC/MS system,Other,21467212.0,
548,1217707,1,2,,103172342,3152,Unspecified,60416369.0,1557.0,,,Time dependent inhibition of CYP2C19 in human liver microsomes at 100 uM by LC/MS system,Other,21467212.0,
549,1217708,1,2,,103172342,3152,Unspecified,84028191.0,1565.0,,,Time dependent inhibition of CYP2D6 (unknown origin) at 100 uM by LC/MS system,Other,21467212.0,
550,1217709,1,2,,103172342,3152,Unspecified,116241312.0,1576.0,,,Time dependent inhibition of CYP3A4 (unknown origin) at 100 uM by LC/MS system,Other,21467212.0,
551,1217710,1,2,,103172342,3152,Unspecified,,,,,Covalent binding in human liver microsomes measured per mg of protein using radiolabelled compound at 10 uM after 1 hr incubation by liquid scintillation counting,Other,21467212.0,
552,1217711,1,2,,103172342,3152,Unspecified,,,,,Metabolic activation in human liver microsomes assessed as [3H]GSH adduct formation rate measured per mg of protein at 100 uM by [3H]GSH trapping assay,Other,21467212.0,
553,1217712,1,2,,103172342,3152,Unspecified,117225.0,1558.0,,,Time dependent inhibition of CYP2C8 (unknown origin) at 100 uM by LC/MS system,Other,21467212.0,
554,1217727,1,2,,103172342,3152,Unspecified,,,,,Intrinsic clearance for reactive metabolites formation per mg of protein in human liver microsomes based on [3H]GSH adduct formation rate at 100 uM by [3H]GSH trapping assay,Other,21467212.0,
555,1217728,1,1,,103172342,3152,Unspecified,,,,,Intrinsic clearance for reactive metabolites formation per mg of protein based on cytochrome P450 (unknown origin) inactivation rate by TDI assay,Other,21467212.0,
556,1217729,1,1,,103172342,3152,Unspecified,,,,,Intrinsic clearance for reactive metabolites formation assessed as summation of [3H]GSH adduct formation rate-based reactive metabolites formation and cytochrome P450 (unknown origin) inactivation rate-based reactive metabolites formation,Other,21467212.0,
557,1220554,1,2,,103172342,3152,Unspecified,,,,,Fraction unbound in Wistar Han rat brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method,Other,21474681.0,
558,1220555,1,2,,103172342,3152,Unspecified,,,,,Fraction unbound in Sprague-Dawley rat brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method,Other,21474681.0,
559,1220556,1,2,,103172342,3152,Unspecified,,,,,Fraction unbound in CD-1 mouse brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method,Other,21474681.0,
560,1220557,1,2,,103172342,3152,Unspecified,,,,,Fraction unbound in Hartley guinea pig brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method,Other,21474681.0,
561,1220558,1,2,,103172342,3152,Unspecified,,,,,Fraction unbound in Beagle dog brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method,Other,21474681.0,
562,1220559,1,2,,103172342,3152,Unspecified,,,,,Fraction unbound in cynomolgus monkey brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method,Other,21474681.0,
563,1220560,1,1,,103172342,3152,Unspecified,,,,,Fraction unbound in human occipital cortex at 1 uM after 6 hrs by equilibrium dialysis method,Other,21474681.0,
564,1224863,1,1,,176483937,3152,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
565,1224863,1,1,,176484861,3152,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
566,1224863,1,1,,316919245,3152,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
567,1225690,1,1,,103172342,3152,Active,584716.0,83817.0,0.015,IC50,Inhibition of AChE in rat cortex using acetylthiocholine iodide as substrate after 15 mins by Ellman's method,Confirmatory,25778991.0,
568,1225691,1,1,,103172342,3152,Active,,,20.7,IC50,Inhibition of BuChE in rat serum using butyrylthiocholine iodide as substrate after 15 mins by Ellman's method,Confirmatory,25778991.0,
569,1225692,1,1,,103172342,3152,Active,14916521.0,,0.11,IC50,Inhibition of electric eel AChE using acetylthiocholine iodide as substrate after 15 mins by Ellman's method,Confirmatory,25778991.0,
570,1225693,1,1,,103172342,3152,Unspecified,,,,,"Selectivity index, ratio of IC50 for rat serum BuChE to IC50 for rat cortex AChE",Other,25778991.0,
571,1225694,1,1,,103172342,3152,Active,113037.0,43.0,0.012,IC50,Inhibition of AChE in human erythrocytes using acetylthiocholine iodide as substrate after 15 mins by Ellman's method,Confirmatory,25778991.0,
572,1225701,1,1,,103172342,3152,Unspecified,112927.0,351.0,,,Inhibition of self-induced Abeta(1 to 42) (unknown origin) aggregation at 25 uM after 24 hrs by Thioflavin T-based fluorometric assay,Other,25778991.0,
573,1225704,1,1,,103172342,3152,Unspecified,112927.0,351.0,,,Inhibition of Cu2+-induced amyloid beta (1 to 42) (unknown origin) aggregation at 25 uM after 24 hrs by thioflavin-T based fluorescence assay,Other,25778991.0,
574,1225707,1,1,,103172342,3152,Unspecified,113037.0,43.0,,,Inhibition of human AChE-induced amyloid beta (1 to 40) (unknown origin) aggregation at 100 uM by thioflavin-T based fluorescence assay,Other,25778991.0,
575,1225714,1,1,,103172342,3152,Inactive,,,,,"Reversal of scopolamine-induced cognitive deficit in Kunming mouse assessed as latency time at 0.5 mg/kg, po administered 1 hr before training trial measured at 24 hrs after training trial by passive avoidance test",Other,25778991.0,
576,1225715,1,1,,103172342,3152,Unspecified,,,,,"Reversal of scopolamine-induced cognitive deficit in Kunming mouse assessed as longer latency time at 5 mg/kg, po administered 1 hr before training trial measured at 24 hrs after training trial by passive avoidance test",Other,25778991.0,
577,1230938,1,1,,103172342,3152,Unspecified,113978.0,4128.0,,,Inhibition of human recombinant MAO-A using kynuramine substrate at 10 uM by spectrophotometric assay,Other,26107513.0,
578,1230940,1,1,,103172342,3152,Unspecified,113980.0,4129.0,,,Inhibition of human recombinant MAO-B using kynuramine substrate at 10 uM by spectrophotometric assay,Other,26107513.0,
579,1230942,1,1,,103172342,3152,Active,113037.0,43.0,0.015,IC50,Inhibition of human recombinant AChE by spectrophotometric Ellman's method,Confirmatory,26107513.0,
580,1230944,1,1,,103172342,3152,Active,116353.0,590.0,4.8,IC50,Inhibition of human serum BuChE by spectrophotometric Ellman's method,Confirmatory,26107513.0,
581,1245372,1,1,,103172342,3152,Inconclusive,,,,,Antioxidant activity assessed as trolox equivalents of AAPH radical scavenging activity preincubated for 15 mins followed by AAPH addition measured every min for 80 mins by fluorescein-based ORAC assay,Other,26337018.0,
582,1245373,1,1,,103172342,3152,Active,21362409.0,100033901.0,8.71,IC50,Inhibition of equine serum BuChE using DTNB as substrate incubated for 5 mins prior to substrate addition measured after 2 mins by Ellman's method,Confirmatory,26337018.0,
583,1245374,1,1,,103172342,3152,Active,14916521.0,,0.049,IC50,Inhibition of electric eel AChE using DTNB as substrate incubated for 5 mins prior to substrate addition measured after 2 mins by Ellman's method,Confirmatory,26337018.0,
584,1245375,1,1,,103172342,3152,Unspecified,,,,,"Selectivity index, ratio of IC50 for equine serum BuChE to IC50 for electric eel AChE",Other,26337018.0,
585,1252806,1,1,,103172342,3152,Active,113037.0,43.0,0.013999999999999999,IC50,Inhibition of human recombinant AChE using acetylthiocholine iodide as substrate preincubated for 5 mins followed by substrate addition by Ellman's method,Confirmatory,26363866.0,
586,1252807,1,1,,103172342,3152,Active,116353.0,590.0,5.6,IC50,Inhibition of human serum BuChE using S-butyrylthiocholine iodide as substrate preincubated for 5 mins followed by substrate addition by Ellman's method,Confirmatory,26363866.0,
587,1252808,1,1,,103172342,3152,Unspecified,,,,,Selectivity ratio of IC50 for human serum BuChE to IC50 for human recombinant AChE,Other,26363866.0,
588,1253473,1,1,,103172342,3152,Active,14916521.0,,0.0599,IC50,Inhibition of electric eel AChE using thiocholine iodide as substrate by Ellman's method,Confirmatory,26454504.0,
589,1253474,1,1,,103172342,3152,Active,21362409.0,100033901.0,3.62,IC50,Inhibition of equine serum BuChE using thiocholine iodide as substrate by Ellman's method,Confirmatory,26454504.0,
590,1253475,1,1,,103172342,3152,Unspecified,,,,,"Selectivity index, ratio of IC50 for equine serum BuChE to IC50 for electric eel AChE",Other,26454504.0,
591,1254985,1,1,,103172342,3152,Active,543754.0,,0.023,IC50,Inhibition of Torpedo californica AChE (type VI-S) using acetylthiocholine iodide as substrate assessed as 5-thio-2-nitrobenzoate anion formation preincubated for 15 mins followed by substrate addition,Confirmatory,26363872.0,
592,1257001,1,1,,103172342,3152,Active,14916521.0,,0.042,IC50,Inhibition of electric eel AChE using acetylthiocholine iodide as substrate preincubated for 15 mins by Ellman's method,Confirmatory,26514744.0,
593,1257002,1,1,,103172342,3152,Active,21362409.0,100033901.0,0.54,IC50,Inhibition of equine serum BuChE using butyrylthiocholine iodide as substrate preincubated for 15 mins by Ellman's method,Confirmatory,26514744.0,
594,1257004,1,1,,103172342,3152,Inconclusive,112927.0,351.0,,,Inhibition of self-induced amyloid beta (1-42) aggregation (unknown origin) at 25 uM after 48 hrs by thioflavin T fluorescence method,Other,26514744.0,
595,1257005,1,1,,103172342,3152,Inconclusive,,,,,Antioxidant activity assessed as DPPH scavenging activity at 10 to 60 ug/ml after 30 mins,Other,26514744.0,
596,1258749,1,1,,103172342,3152,Active,,,0.0067,IC50,"BindingDB_Patents: Inhibition Assay. The inhibitory activity of the enzyme acetylcholinesterase (AChE) was evaluated by the Ellman method (Biochem. Pharmacol. 1961, 7, 88) using an electric eel as an AChE neuronal model (Electrophorus electricus) and acetylthiocholine iodide (0.35 mM) as substrate. The reaction took place in a final volume of 3 mL of a 0.1 M phosphate buffer solution, pH 8.0, containing 0.035 units of AChE and used a 0.35 mM solution of 5,5'-dithio-bis(2-nitrobenzoic acid) (DTNB) to produce the 5-thio-2-nitrobenzoic acid anion. Inhibition curves were performed in triplicate by incubating at least nine inhibitor concentrations for 10 min. A triplicate sample without inhibitor was always present so as to be aware of 100% of the AChE activity. After this time, the substrate was added to 0.35 mM acetylthiocholine iodide, from a 10 mM stock solution. Loss of color was observed at 412 nm in a spectrophotometric reader having 96 well plates.",Confirmatory,,
597,1258750,1,1,,103172342,3152,Unspecified,113979.0,29253.0,854800.0,IC50,"BindingDB_Patents: Inhibition Assay. The inhibitory activity of monoamine oxidases A and B was assessed by the Fowler and Tipton radiometric method (Biochem Pharmacol 1981, 30, 3329) using a purification of rat liver mitochondria as the source of enzymes. The inhibitory activity of MAO-B was compared to 25 ul of [14C]-phenylethylamine (PEA), 20 uM of activity, 2.5 mCi/mmol. The inhibitory activity of MAO-A was compared to 25 ul of [14C]-(5-hydroxytriptamine) (5-HT), 100 uM of activity, 0.5 mCi/mmol. Inhibition curves were performed in triplicate by incubating at least nine inhibitor concentrations for 30 min. A triplicate sample without inhibitor was always present so as to be aware of 100% of the MAO activity. The reaction took place with the addition of the substrate in a final volume of 225 ul of 50 mM phosphate buffer, pH 7.4, containing 20 ul of rat liver mitochondria at a concentration of 5 mg/ml. The reaction was carried out under continuous stirring at 37 C. for 4 minutes.",Confirmatory,,
598,1258751,1,1,,103172342,3152,Unspecified,124028639.0,25750.0,15400.0,IC50,"BindingDB_Patents: Inhibition Assay. The inhibitory activity of monoamine oxidases A and B was assessed by the Fowler and Tipton radiometric method (Biochem Pharmacol 1981, 30, 3329) using a purification of rat liver mitochondria as the source of enzymes. The inhibitory activity of MAO-B was compared to 25 ul of [14C]-phenylethylamine (PEA), 20 uM of activity, 2.5 mCi/mmol. The inhibitory activity of MAO-A was compared to 25 ul of [14C]-(5-hydroxytriptamine) (5-HT), 100 uM of activity, 0.5 mCi/mmol. Inhibition curves were performed in triplicate by incubating at least nine inhibitor concentrations for 30 min. A triplicate sample without inhibitor was always present so as to be aware of 100% of the MAO activity. The reaction took place with the addition of the substrate in a final volume of 225 ul of 50 mM phosphate buffer, pH 7.4, containing 20 ul of rat liver mitochondria at a concentration of 5 mg/ml. The reaction was carried out under continuous stirring at 37 C. for 4 minutes.",Confirmatory,,
599,1258752,1,1,,103172342,3152,Active,,,7.4,IC50,"BindingDB_Patents: Inhibition Assay. The inhibitory activity of the enzyme acetylcholinesterase (AChE) was evaluated by the Ellman method (Biochem. Pharmacol. 1961, 7, 88) using an electric eel as an AChE neuronal model (Electrophorus electricus) and acetylthiocholine iodide (0.35 mM) as substrate. The reaction took place in a final volume of 3 mL of a 0.1 M phosphate buffer solution, pH 8.0, containing 0.035 units of AChE and used a 0.35 mM solution of 5,5'-dithio-bis(2-nitrobenzoic acid) (DTNB) to produce the 5-thio-2-nitrobenzoic acid anion. Inhibition curves were performed in triplicate by incubating at least nine inhibitor concentrations for 10 min. A triplicate sample without inhibitor was always present so as to be aware of 100% of the AChE activity. After this time, the substrate was added to 0.35 mM acetylthiocholine iodide, from a 10 mM stock solution. Loss of color was observed at 412 nm in a spectrophotometric reader having 96 well plates.",Confirmatory,,
600,1259325,1,2,,336955399,3152,Inactive,4504843.0,3763.0,,,Discovering small molecule activators of G protein-gated inwardly-rectifying potassium subunit 2 (GIRK2) containing channels utilizing methyl-2 4-pentanediol (MPD) for partial channel activation during screening,Screening,,
601,1259416,1,2,,340079845,3152,Inactive,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
602,1259416,1,2,,375174997,3152,Inactive,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
603,1259421,1,1,,340079845,3152,Inactive,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
604,1259421,1,1,,375174997,3152,Inactive,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
605,1259423,1,2,,355016858,3152,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
